INDEX OF SUBJECTS FOR VOLUME 50

Abscess brain, *N. otitidiscaviarum*, 101 muscular, *S. intermedius*, 480
Acinetobacter spp. *A. baumannii*, class 1 integrons and antibiotic resistance, 71
clinical importance of extended-spectrum β-lactamase, 642
Actin
staphylococcal, cytoskeletal, 35
Actinobacillus actinomycetemcomitans
cdt genes, 860
Adenovirus
detection of antigens, 203
rapid isolation of nucleic acid, 571
Adherence
A. caviae to HEp-2 cells, 313
C. difficile to intestinal epithelial cells, 526
H. ducreyi to human epithelial cells, 449
H. pylori to cell lines, 320
mycobacterial α2-laminins in, 23
P. aeruginosa to epithelial respiratory cells, 183
Adhesins
putative, of *H. pylori*, 215
Adult respiratory distress syndrome (ARDS), 49
Aeromonas caviae
enhancement of virulence, 303
Agglutination
latex, ultrasound-enhanced, 203
AIDS patients
investigation of CSF, 165
simian polyomavirus SV40, 165
Aminoglycoside-resistant *C. freundii*, 636
Amoebic encephalitis, 205
Animal models *see* Mouse model, Rat model, Sheep model
Anthrax, 702
Antibiotic resistance
1% proportion method, 1018
A. baumannii, and class 1 integrons, 71
aminoglycoside, and *C. freundii*, 636
cefotaxime, and *S. pneumoniae*, 173
cyclohexane resistance in salmonellae, 919
enterococci from coastal bathing waters, 1001
fusidic acid, increased with salicylate, 104
glycopeptide, and *E. faecium*, 682
hetero-resistance, 1018
of *H. pylori*, 486
imipenem, and *B. fragilis*, 107
methicillin, and *S. aureus* (MRSA), 476, 558, 588, 732, 909, 940, 1018
multiresistance of salmonellae, 919
mupirocin, and *S. aureus*, 909
penicillin, and *S. pneumoniae*, 828
quinolones, and enteroaggregative *E. coli*, 996
vancomycin, and enterococci, 695
vancomycin, and *S. aureus*, 1018
Antibiotics and other antimicrobial substances
activity of diallyl sulphides, 646
bacitracin, in isolation of *H. influenzae*, 472
bactericidal activity of quinolones, 565
detection of antibiotic-killed *E. coli* by PCR, 243
fluconazole susceptibility of *Candida* spp., 375
inhibition of *C. albicans* hyphae by fluconazole, 78
isoniazid and catalase activity, 675
natural susceptibility of *Klebsiella* spp., 396
susceptibility of enteroaggregative *E. coli*, 996
susceptibility of *V. cholerae*, 879
see also Antiseptics
Antibodies
against *B. burgdorferi*, 889
against *Brucella* spp., 663, 965
against *E. coli* O157 LPS, 345
against human papillomavirus, 468
against *M. paratuberculosis*, 795
against *P. brasiliensis*, 127
against *V. cholerae*, 489, 499
antiphospholipid, 965
anti-platelet activating factor, 965
in mimotope vaccine development, 937
Antigens
adenovirus, 203
B. burgdorferi, 577, 889, 896
B. pseudomallei, 330
B. pseudomallei culture filtrate, 55
H. pylori, 1021
L. pneumophila, 509
in mimotope vaccine development, 937
M. paratuberculosis, 795
novel, of *S. anginosus*, 952
rotavirus, 203
somatic, of *P. brasiliensis*, 127
type specificity of group A streptococci, 1
V. cholerae, 489, 499
Y. pestis, 13, 969, 979
Antiseptics
antibacterial effects on skin, 284
API 20C Aux system, 1105
Arthropathy, 627
Aspergillus spp. *A. fumigatus*, airway colonisation in cystic fibrosis, 367
detection and differentiation of pathogenic/non-pathogenic species, 653
Atherosclerosis, 228

Bacillus anthracis
susceptibility of irradiated mice, 702
Bacitracin
in isolation of *H. influenzae*, 472
Bacteraemia
staphylococci, 940
vancomycin-resistant enterococci, 695
Bacteroides fragilis
resistance to imipenem, 107
Balamuthia mandrillaris
infection and characteristics, 205
Berberine
in detection and differentiation of pathogenic/non-pathogenic *Aspergillus* spp., 653
Bifidobacteria
effect of carbohydrates, 152
metabolism, and prebiotic substances, 833
Binax *Legionella* Urinary Enzyme Immunoassay, 509
BinaxNOW immunochromatographic assay, 509
Biofilms
S. epidermidis, 582
Biotest *Legionella* Urin Antigen Enzyme Immunoassay, 509
Blood–brain barrier, 812
Blood cultures
B. burgdorferi, 896
detection of antibiotic-killed *E. coli*, 243
BOOK REVIEWS
Bacteria in Biology, Biotechnology and Medicine, 5th edition (P. Singleton), 391
Biochemistry and the Molecular Biology of Antimicrobial Drug Action, 5th edition (T. J. Franklin and G. A. Snow), 298
Combination Vaccines – Development, Clinical Research and Approval (edited by R. W. Ellis), 109
Frontiers in Molecular Biology: DNA Virus Replication (edited by A. J. Cann), 297
Glycomicrobiology (edited by R. J. Doyle), 483
Handbook of Bacterial Adhesion: Principles, Methods, and Applications (edited by Y. H. An and R. J. Friedman), 391
Human Virology, 2nd edition (L. Collier and J. Oxford), 390
Infectious Diseases and Arthropods (J. Goddard), 298
Methods in Molecular Biology, volume 145: Bacterial Toxins, Methods and Protocols (edited by O. Holst), 390
Methods in Molecular Medicine, Antibiotic Resistance: Methods and Protocols (edited by S. H. Gillespie), 391
Methods in Molecular Medicine, Rotaviruses: Methods and Protocols (edited by J. Gray and U. Desselberger), 204

Mycobacteria, Molecular Biology and Virulence (edited by C. Ratledge and J. Dale), 297
Oral Microbiology, 4th edition (P. Marsh and M. V. Martin), 297
Serodiagnosis of the Infectious Disease (N. Cimolai), 109
Sexually Transmitted Diseases, Vaccines, Prevention, and Control (edited by L. R. Stanberry and D. I. Bernstein), 390
Trematode Infections and Diseases of Man and Animals (V. Kumar), 204
Bordetella spp.
B. bronchiseptica, analysis of molecular typing methods, 255
B. bronchiseptica, variation in flagellin gene, 255
B. parapertussis, detection by real-time PCR, 436
B. pertussis, detection by real-time PCR, 436
Borna disease virus
in psychiatric disorders, 579
Borrelia spp.
B. burgdorferi, characterisation of isolates from blood, 896
B. burgdorferi, ELISA for antigens in CSF, 577
B. burgdorferi, importance of genome sequencing, 843
B. burgdorferi, reactivity of dog sera to antigens, 889
B. lusitaniae, pathology of infection, 1055
Brain abscess, 101
Brucella spp.
dipstick assay for IgM antibodies, 663
immune response, 965
Brucellosis, 663, 965
Burkholderia spp.
B. cepacia, flagellin genotyping, 728
B. cepacia, invasion of respiratory epithelial cells, 594
B. cepacia, localisation in cystic fibrosis lungs, 535
B. pseudomallei, production of oxalate, 655
B. pseudomallei, cloning and characterisation of *malE*, 330
B. pseudomallei, immunoglobulin classes and subclasses in melioidosis, 55
B. pseudomallei, melioidosis as clinical model for gram-negative sepsis, 657
Burns unit
persistence of methicillin-resistant *S. aureus*, 558

Camellia sinensis (tea)
anti-cariogenic properties, 299
Campylobacteriosis, 933
Campylobacters
cdt genes in isolates from broilers, 1087
C. jejuni, molecular epidemiology, 1075
C. jejuni, peritonitis in peritoneal dialysis, 935
in domestic animals and handlers in Calcutta, 933
isolation from faeces, 659
Candida spp.
C. albicans, expression of secreted aspartyl proteinases, 743
C. albicans, inhibition of hyphae by fluconazole, 78
comparison of identification methods, 1105
C. parapsilosis, PCR identification, 441
fluconazole susceptibility, 375
Candidosis, 743
Candifast system, 1105
Capsule
of *K. pneumoniae*, 456
Carbohydrates
effect on bifidobacteria, 152
effect on *E. coli*, 152
mimotope vaccine development, 937
Caries, 299
Catalase-like activity
M. leprae, 675
Cefotaxime
resistance of *S. pneumoniae*, 173
Chemokines
in meningococcal disease, 847
Chemotaxis
inhibition by *L. pneumophila* protease, 517
Children
nasopharyngeal carriage of respiratory pathogens, 1095
penicillin-resistant *S. pneumoniae* in, 828
pyelonephritogenic *E. coli*, 650
Chinese leek oil, antimicrobial activity, 646
Chlamydia
C. pneumoniae, absence of RNA in atheromas, 228
C. pneumoniae, and iron restriction, 223
C. trachomatis, in female infertility, 902
C. trachomatis, and iron restriction, 223
genome sequencing, 843
Chlorhexidine
antibacterial effects on skin, 284
Chloride secretion
thermostable direct haemolysin-induced, 870
Citrobacter freundii
aminoglycoside resistance, 636
Clostridium difficile
adherence to intestinal epithelium, 526
colonisation and transmission in healthy individuals, 720
epidemiological typing, 407
PCR ribotyping, 1082
tcdE gene, 613
Colitis, chronic, 421
Colony stimulating factors
in meningococcal disease, 853
Corynebacteria
laboratory diagnosis of diphtheria, 1006
Cryptococcus neoformans
anticryptococcal protein in CSF, 83
hetero-resistance, 1018
Cryptosporidium spp.
C. felis from human faeces, 293
'dog-type' from human faeces, 293
CSF
anticryptococcal protein in, 83
cytokines and chemokines in meningococcal disease, 853
failure to detect *B. burgdorferi* antigens, 577
investigation of AIDS patients, 165
Culture medium
detection and differentiation of pathogenic/non-pathogenic *Aspergillus* spp., 653
expression of acid-stable proteins of *Y. pestis*, 979
gellan gum, and PCR applications, 108
isolation of *H. influenzae* from sputum, 472
for methicillin-resistant *S. aureus*, 476
Cyclohexane
resistance of salmonellae, 919
Cystic fibrosis, 261, 367, 535
Cytokines
induction by *M. luteus* teichuronic acids, 4
induction by novel *S. anginosus* antigen, 952
in *K. pneumoniae* pneumonia, 456, 959
lethality of mousepox virus, 936
in meningococcal disease, 847
Cytolethal distending toxin genes
A. actinomycetemcomitans, 860
in campylobacters, 1087
H. ducreyi, 860

Diallyl sulphides
antimicrobial activity, 646
Diarrhoea
characterisation of *V. cholerae* rough variants, 268
detection of enteroinvasive *E. coli* in faeces, 667
detection of *Shigella* spp. in faeces, 667
enteroaggregative *E. coli*, 996
traveller's, 996
V. cholerae, characterisation of isolates, 879
virulence of *A. caviae*, 303
Diphtheria, 1006
DNA
application of FAFLP, 393
chip and molecular technologies, 111
detection of *M. leprae*, 177
detection of *P. micros* by PCR, 249
fingerprinting of *V. cholerae*, 879
molecular analysis of *P. alcalifaciens*, 29
M. tuberculosis, in ancient Egyptian tissue samples, 355
RAPD analysis of *P. aeruginosa*, 261
RAPD analysis of *S. apiospermum*, 925
rapid isolation from adenoviruses, 571
DNAases
serum, and detection of *E. coli* by PCR, 243

Dog sera
reactivity to *B. burgdorferi*, 889
Drug abuse, intravenous, 101
Electron microscopy
immunogold labelling, 743
interaction of *E. coli* with primary cell cultures, 759
interaction of *Yersinia* spp. with platelets, 1030
invasion of respiratory epithelial cells by *B. cepacia*, 594
Sap expression by *C. albicans*, 743
scanning, 759
transmission, 594
ELISA
capture, 1100
competitive inhibition, 577
detection of *B. burgdorferi* antigens, 577
detection of *T. gondii* infection, 1100
reactivity of dog sera to *B. burgdorferi* antigens, 889
Encephalitis, granulomatous amoebic, 205
Endo-β-N-acetylglucosaminidase activity
in enterococci, 620
Enterococcus spp.
antibiotic resistance patterns, 1001
bacteraemia, 695
E. faecium, glycopeptide-resistant, 682
E. faecium, VanA and VanB elements, 682
endo-β-N-acetylglucosaminidase activity, 620
from coastal bathing waters, 1001
vancomycin-resistant, 695
Enteropathogens
she pathogenicity island in, 780
Enzyme immunoassay (EIA)
detection of *H. pylori* in faeces, 1021
L. pneumophila, 509
Epidemiology
A. fumigatus colonisation in cystic fibrosis, 367
B. mandrillaris, 205
CDT production in campylobacters from broilers, 1087
DNA chips and molecular technologies, 111
H. influenzae in Taiwan, 277
meningococcal disease, 986
molecular, of *C. jejuni*, 1075
nasopharyngeal carriage of respiratory pathogens, 1095
P. aeruginosa in cystic fibrosis patients, 261
S. epidermidis infections, 582
typing methods for *C. difficile*, 407
verocytotoxin-producing *E. coli*, 135
Escherichia coli
antibody response to O157 LPS, 345
attaching and effacing lesions in sheep, 752
blood–brain barrier permeability in sepsis, 812
cytopathic effects of outer-membrane proteins, 602
detection by PCR assay, 667
effect of carbohydrates, 152
enteroaggregative (EAggEC), 996
enterohaemorrhagic (EHEC), 201, 752, 759
enteroinvasive (EIEC), 667
enteropathogenic (EPEC), 602, 759
interaction with primary cell cultures, 759
maltoporin, 602
pyelonephritogenic, 650
secretory virulence factor EspB, 602
she pathogenicity island, 780
Shiga-like toxin-producing (STEC), 90
susceptibility patterns, 996
in traveller's diarrhoea, 996
verocytotoxin-producing (VTEC), 135
Eubacterium spp.
characterisation of strains from oral infections, 947
Exotoxins
P. aeruginosa exotoxin A, 822
External quality assessment (EQA)
laboratory diagnosis of diphtheria, 1006

Faeces
antagonism of microbiota against *V. cholerae*, 161
detection of enteroinvasive *E. coli*, 667
detection of *H. pylori*, 1021
detection of *Shigella* spp., 667
isolation of enteric pathogens, 659
recovery of unusual *Cryptosporidium* spp., 293
FAFLP (fluorescent amplified fragment length polymorphism) analysis
genotyping of methicillin-resistant *S. aureus*, 588
genotyping of *N. meningitidis*, 991
technique and applications, 393
FemtoLab H. pylori system, 1021
Fibronectin
in meningococcal disease, 853
Fimbriae
S. enterica serotype Enteritidis, 191, 1049
Flagellin, genotyping
B. bronchiseptica, 255
B. cepacia, 728
Flow cytometry
adherence of *C. difficile* to intestinal epithelium, 526
susceptibility of *Candida* spp. to fluconazole, 375
Fluconazole
inhibition of *C. albicans* hyphae, 78
susceptibility of *Candida* spp., 375
Foot rot, ovine, 1061
FUN-1 staining
susceptibility of *Candida* spp. to fluconazole, 375
Fungichrom I system, 1105
Fusidic acid
increased resistance mutations with salicylate, 104
Fusobacterium nucleatum
effects of peroxidase systems, 42

Galacto-oligosaccharides (GOS)
bacterial metabolism, 833
Gardnerella vaginalis
hetero-resistance, 1018
Garlic oil, antimicrobial activity, 646
Gastro-enteritis, 143
Gellan gum, 108
Genes
analysis of mupirocin resistance in MRSA, 909
B. cepacia flagellin genotyping, 728
cdt, among *A. actinomycetemcomitans*, 860
cdt among campylobacters, 1087
cdt, among *H. ducreyi*, 860
characterisation of *V. cholerae* rough variants, 268
cloning and characterisation of *malE* in *B. pseudomallei*, 330
genome sequencing of difficult pathogenic bacteria, 843
holin function of *C. difficile tcdE* gene, 613
human serotype G6 and G8 rotaviruses, 462
imipenem resistance of *B. fragilis*, 107
increased fusidic acid resistance mutations with salicylate, 104
molecular epidemiology of *C. jejuni*, 1075
P. mirabilis super-swarming mutants, 1039
role in plague virulence, 1015
type III secretion systems and pathogenicity islands, 116
typing of aminoglycoside-resistant *C. freundii*, 636
typing of pyelonephritogenic *E. coli*, 650
typing of *V. cholerae*, 879
van elements in glycopeptide-resistant enterococci, 682
variation in *B. bronchiseptica* flagellin gene, 255
in *Y. pestis* fraction I biosynthesis, 969
Genital tract infection
C. trachomatis, 902
human papillomavirus, 468
M. genitalium, 383
Glycopeptide-resistant *E. faecium*, 682
Granuloma formation
R. aurantiacus-induced, 688
Growth-related gene product-α (GRO-α)
in meningococcal disease, 853
Haemagglutinins
H. alvei, 208
Haemolysin
thermostable direct, of *V. parahaemolyticus*, 870
Haemophilus spp.
H. ducreyi, *cdt* genes, 860
H. ducreyi, effect of temperature on interaction with epithelial cells, 449
H. influenzae, epidemiological studies in Taiwan, 277
H. influenzae, isolation from sputum, 472

H. influenzae, nasopharyngeal carriage in children, 1095
Hafnia alvei
putative virulence factors, 208
Helicobacter spp.
H. pylori, adherence, 320
H. pylori, antimicrobial resistance, 485
H. pylori, detection in faeces, 1021
H. pylori, inhibition of infection by milk, 430
H. pylori, new therapeutic targets, 485
H. pylori, non-opsonic activation of neutrophils, 787
H. pylori, non-standard activity of LPS, 865
H. pylori, putative adhesins, 215
novel, in monkeys with chronic colitis, 421
Heparan sulphate-binding proteins
of *H. pylori*, 215, 320
of *P. aeruginosa*, 183
Heparin-binding protein, staphylococcal, 547
HLA-B27 in infection, 385
Holin function
of *C. difficile tcdE* gene, 613
Human papillomavirus (HPV)
antibody response and laryngeal papillomatosis, 468
Hybridisation
in-situ, detection of *C. trachomatis*, 902

Imipenem
resistance of *B. fragilis*, 107
Immune response
mimotope vaccine strategies, 937
to *B. burgdorferi* antigens, 889
to *Brucella* spp., 965
to human parvovirus B19 NS1 protein, 627
to *P. aeruginosa*, 822
to *V. cholerae*, 489
Immunisation
mice against *Y. pestis*, 13
mice and rabbits against *V. cholerae*, 499
rabbits against *M. paratuberculosis*, 795
Immunoblot analysis
reactivity of dog sera to *B. burgdorferi* antigens, 889
Immunoblotting
detection of *T. gondii* infection, 1100
Immunoglobulins
against *E. coli* O157 LPS, 345
dipstick-IgM assay for brucellosis, 663
IgA, interference in diagnosis of brucellosis, 663
IgA, and *V. cholerae* infection, 489
IgG, subclasses in melioidosis, 55
serological markers for toxoplasmosis, 62
specific classes and subclasses in melioidosis, 55
Immuno-gold lateral flow test, 203
Immunosuppressed patients
P. carinii colonisation, 198
see also AIDS patients
Impetigo, 2
Infertility, female, 902
Integrons
class 1, of *A. baumannii*, 71
Interferons (IFN)
IFN-α , in meningococcal disease, 853
IFN-β, in meningococcal disease, 853
IFN-γ, protection against *K. pneumoniae* pneumonia, 959
Interleukins
IL-1, in meningococcal disease, 850, 855
IL-1 receptor antagonists, in meningococcal disease, 852, 855
IL-2, in meningococcal disease, 851
IL-4, expression by mousepox virus, 936
IL-4, in meningococcal disease, 852
IL-6, induction by *M. luteus* teichuronic acids, 4
IL-6, in meningococcal disease, 851, 855
IL-8, in meningococcal disease, 853
IL-10, in meningococcal disease, 852, 855
IL-10, production in *K. pneumoniae* pneumonia, 456
IL-12, in meningococcal disease, 851
soluble IL-6 receptor (sIL-6R), in meningococcal disease, 852
Inulin
bacterial metabolism, 833
Iron restriction
influence on chlamydia, 223
Isoniazid
relationship with catalase, 675

Klebsiella spp.
K. pneumoniae, capsule, 456
K. pneumoniae, cytokine production in pneumonia, 456, 959
natural antibiotic susceptibility, 396

α-Lactamase
extended-spectrum, clinical importance, 642
Lactobacilli
lectin typing, 1069
α2-Laminins
mycobacterial, in adherence, 23
Laryngeal papillomatosis, 468
Latex agglutination assay, 203
Lectin typing
lactobacilli, 1069
Legionella pneumophila
protease, and phagocyte function, 517
urinary antigen detection, 509
Leptospira fainei
as a human pathogen, 96

Leukaemia/leucocyte inhibitory factor (LIF)
in meningococcal disease, 851
Lipo-oligosaccharide (LOS)
N. meningitidis, 847, 937

Lipopolysaccharide (LPS)
atypical core structure in salmonellae, 339
of *E. coli* O157, antibody response, 345
enhanced VEGF production by monocytes, 233
H. pylori, non-standard activity, 865
modified, of *Y. pestis*, 979
smooth, of *Brucella* spp., 663
Lyme borreliosis, 896
Lymphocytes
recognition of parvovirus B19 NS1 protein, 627

Macrophage inflammatory protein-1α (MIP-1α)
in meningococcal disease, 853
Macrophages
cytokine induction by *M. luteus* teichuronic acids, 4
Macro-restriction analysis
B. bronchiseptica, 255
Maltoporin
of *E. coli*, 602
Maxted, Winston R., 1
Media *see* Culture medium
Melioidosis, 55, 330
clinical model for gram-negative sepsis, 657
Meningococcal disease
cytokines and chemokines in, 847
rising incidence in Belgium, 986
Metabolism
analysis of difficult pathogenic bacteria, 843
non-digestible oligosaccharides, 833
Methicillin
resistant *S. aureus* (MRSA), 476, 558, 588, 732, 909, 940, 1018
Micrococcus luteus
induction of cytokines by teichuronic acids, 4
Milk
inhibition of *H. pylori* infection, 430
Mimotope vaccines, 937
Monoclonal antibodies
against atypical LPS of salmonellae, 339
against rotaviruses, 462
against *Y. pestis*, 13, 969
Monocyte chemotactic protein-1 (MCP-1)
in meningococcal disease, 853
Monocytes
LPS-stimulated, and VEGF production, 233
Moraxella catarrhalis
nasopharyngeal carriage in children, 1095
Mouse model
B. anthracis infection, 702

B. cepacia respiratory challenge, 594
cytokine induction by *M. luteus* teichuronic acids, 4
detection of *T. gondii* infection, 1100
inhibition of *H. pylori* infection, 430
K. pneumoniae pneumonia, 959
M. genitalium infection, 383
P. aeruginosa pneumonia, 822
pathology of *B. lusitaniae* infection, 1055
rabies virus infection, 238
virulence of *A. caviae*, 303
Mousepox virus
enhanced lethality, 936
IL-4-expressing, 936
Mucositis, staphylococcal, 940
Multilocus enzyme electrophoresis (MLEE)
typing of *S. apiospermum*, 925
Multilocus sequence typing (MLST)
epidemiology of meningococcal disease, 986
genotyping of *N. meningitidis*, 991
Mupirocin
resistance of *S. aureus*, 909
Mycobacteria
α2-laminins in adherence, 23
hetero-resistance, 1018
importance of genome sequencing, 843
M. fortuitum, bactericidal activity of quinolones, 565
M. leprae, catalase-like activity, 675
M. leprae, PCR primers, 177
M. paratuberculosis, novel antigens, 795
M. tuberculosis, DNA in ancient Egyptian tissue samples, 355
M. tuberculosis, hetero-resistance, 1018
M. tuberculosis, inhibition by phytosiderophore, 916
M. tuberculosis, IS*6110* transposition in, 805
M. tuberculosis, variation in molecular typing, 749
plasmids, 575
Mycoplasmas
M. genitalium, model of genital tract infection, 383
M. pneumoniae, in model of genital tract infection, 383

Neisseria meningitidis
comparison of genotyping methods, 991
cytokines and chemokines in disease, 847
epidemiology of disease, 986
Nephritis, 2
Neuroborreliosis, 577
Neurological disorders, 165
Neutrophils
bactericidal dysfunction and ARDS, 49
non-opsonic activation by *H. pylori*, 787
Nitric oxide
induced by novel *S. anginosus* antigen, 952
in meningococcal disease, 853
role in rabies virus infection, 238
Nocardia otitidiscaviarum
primary brain abscess, 101
Norwalk-like virus
gastro-enteritis outbreaks, 143

Oligosaccharides
non-digestible, metabolism, 833
Oral bacteria
characterisation of *Eubacterium*-like strains from oral infections, 947
detection of *P. micros* by PCR, 249
ecology of *Staphylococcus* spp., 940
effects of peroxidase systems, 42
Osteomyelitis, iliac, 480
Ovine foot rot, 1061
Oxalate
production by *B. pseudomallei*, 655
Oxidative burst
inhibition by *L. pneumophila* protease, 517

Paracoccidioides brasiliensis
antibody responses, 127
Paracoccidioidomycosis, 127
Parvovirus
human, B19 NS1 protein and arthropathy, 627
Pathogenicity islands
she, in enteropathogens, 780
type III secretion systems, 116
PCMX
antibacterial effects on skin, 284
PCR
analysis of atheromas for *C. pneumoniae* RNA, 228
B. cepacia flagellin genotyping, 728
C. difficile, colonisation and transmission, 720
detection of antibiotic-killed *E. coli*, 243
detection of *B. pertussis* and *B. parapertussis*, 436
detection of *C. trachomatis*, 902
detection of enteroinvasive *E. coli* in faeces, 667
detection of *H. pylori* in faeces, 1021
detection of *P. micros*, 249
detection of *Shigella* spp. in faeces, 667
detection of *T. gondii* infection, 1100
epidemiology of meningococcal disease, 986
gellan gum in microbiological media, 108
genotyping of *P. carinii*, 198
identification of *C. parapsilosis*, 441
molecular analysis of *P. alcalifaciens*, 29
M. tuberculosis DNA in ancient Egyptian tissue samples, 355
primers for detection of *M. leprae*, 177
RAPD typing, 29, 90
real-time, 436
REA of STEC O157 RAPD amplicons, 90
ribotyping of *C. difficile*, 407, 1082
Penicillin
resistance of *S. pneumoniae*, 828
Penicillin-binding proteins
of *S. pneumoniae*, 828
Peptostreptococcus micros
detection by PCR, 249
Periodontal disease, 940
Peritoneal dialysis, 935
Peritonitis, 935
Peroxidase systems
effects on oral bacteria, 42
Phagocytes
inhibition of function by *L. pneumophila* protease, 517
Phagocytosis
protection against *K. pneumoniae* pneumonia, 959
Phosphatidylcholine
in brucellosis, 965
Phytosiderophore
inhibition of *M. tuberculosis*, 916
Plague, 1015
Plasmids
mycobacteria, 575
pLCR-encoded proteins of *Y. pestis*, 13
profiles of *B. burgdorferi*, 896
Plasminogen activator inhibitor (PAI-1)
in meningococcal disease, 853
Platelet activating factor
in brucellosis, 965
Platelets
interaction with *Yersinia* spp., 1030
Pneumococci *see Streptococcus pneumoniae*
Pneumocystis carinii
genotyping, 198
pulmonary colonisation in HIV-negative patient, 198
Pneumonia
K. pneumoniae, 456, 959
P. aeruginosa, 822
PNPG (*p*-nitrophenylglycerol)
resistant *P. mirabilis* super-swarming mutants, 1039
Polysaccharides
mimotope vaccine development, 937
Porphyromonas gingivalis
effects of peroxidase systems, 42
Porpoises, novel serotype of *S. enterica*, 415
Povidone iodine
antibacterial effects on skin, 284
Prebiotic substances, 833
Pregnancy, ectopic, 902
Premier Platinum HpSA system, 1021
Prostaglandins
in meningococcal disease, 853
Protease

of *L. pneumophila*, 517
Protein
acid-stable, of *Y. pestis*, 979
anticryptococcal, in CSF, 83
heparan sulphate-binding, of *H. pylori*, 320
M and T antigens of group A streptococci, 1
novel antigens of *M. paratuberculosis*, 795
outer-membrane, of *A. caviae*, 313
outer-membrane, of *E. coli*, 602
outer-membrane, of *Y. pestis*, 979
parvovirus B19 NS1, 627
penicillin-binding, of *S. pneumoniae*, 828
peptide-based vaccine strategies, 937
pLCR, of *Y. pestis*, 13
profiles of *B. burgdorferi*, 896
staphylococcal protein A, 35
staphylococcal heparin-binding, 547
VP7, of human serotype G6 and G8 rotaviruses, 462
Proteinase
secreted aspartyl, of *C. albicans*, 743
Proteus mirabilis
PNPG-resistant super-swarming mutants, 1039
Providencia alcalifaciens
molecular analysis, 29
Pseudomonas aeruginosa
adherence to respiratory epithelial cells, 183
clinical importance of extended-spectrum β-lactamase, 642
in cystic fibrosis, 261
exotoxin A in mouse model of pneumonia, 822
molecular epidemiology, 261
neutrophil bactericidal dysfunction and ARDS, 49
Psychiatric disorders, 579
Pulmonary colonisation
P. carinii, 198
Pulsed-field gel electrophoresis (PFGE)
C. difficile, colonisation and transmission, 720
characterisation of *B. burgdorferi*, 896
epidemiological study of *H. influenzae*, 277
epidemiology of meningococcal disease, 986
genotyping of methicillin-resistant *S. aureus*, 588
molecular epidemiology of *C. jejuni*, 1075
molecular typing of *B. bronchiseptica*, 255
molecular typing of *C. difficile*, 407
variations in typing of *M. tuberculosis*, 749

Quality assessment
laboratory diagnosis of diphtheria, 1006
Quinolones
bactericidal activity in *M. fortuitum* model, 565
resistance of enteroaggregative *E. coli*, 996

Rabies virus role of nitric oxide in pathogenesis, 238
Radiation ionising, and *B. anthracis* infection, 702
RANTES
in meningococcal disease, 853
Rat model
intestinal colonisation by *S.* Enteritidis, 191
survival of *S.* Enteritidis SEF 21 fimbriae, 1049
Reactive arthritis, 385
Respiratory pathogens
nasopharyngeal carriage, 1095
Restriction endonuclease analysis
adenoviruses, 571
molecular epidemiology of *C. jejuni*, 1075
Restriction fragment length polymorphism (RFLP) analysis
B. bronchiseptica, 255
B. cepacia flagellin genotyping, 728
Rhesus monkeys
novel *Helicobacter* spp. and chronic colitis, 421
Rhodococcus aurantiacus
granuloma formation, 688
Ribotyping
automated, 277
C. difficile, 407, 720, 1082
H. influenzae, 277
V. cholerae, 879
Rickettsias
genome sequencing, 843
Rotaviruses
detection of antigens, 203
human serotype G6 and G8, 462

Salicylate
increased fusidic acid resistance mutations, 104
Salmonellae
atypical LPS core structure, 339
cyclohexane resistance, 919
isolation from faeces, 659
multiresistance patterns, 919
novel serotype from harbour porpoises, 415
S. enterica, *mar* locus and virulence, 770
S. enterica, SEF 21 fimbriae, 191, 1049
S. enterica, *she* pathogenicity island, 780
serotype Enteritidis, 191, 1049
serotype Typhimurium, 770, 780
Scedosporium apiospermum
strain differentiation, 925
Schwann cells
mycobacterial *a*2-laminins in adherence, 23
SDS-PAGE
protein profiles of *B. burgdorferi*, 896
Sepsis
blood-brain barrier permeability and TNF-α, 812
E. coli, 812
gram-negative, melioidosis as clinical model, 657
meningococcal disease, 847
S. pneumoniae, 812
Serogrouping
V. cholerae, clinical and environmental isolates, 879
Serology
diagnostic antiserum for *V. cholerae*, 499
dipstick-IgM assay for brucellosis, 663
markers for diagnosis of toxoplasmosis, 62
Serotyping
group A streptococci, 1
Serum
DNAases, and detection of *E. coli*, 243
resistance of *H. alvei*, 208
Sheep
novel spirochaete from severe virulent foot rot, 1061
Sheep model
E. coli O157, attaching and effacing lesions, 752
Shiga-like toxin-producing *E. coli* (STEC), 90
Shigella spp.
detection by PCR assay, 667
she pathogenicity island, 780
Siderophores
inhibition of *M. tuberculosis* by phytosiderophore, 916
production by *H. alvei*, 208
Simian polyomavirus SV40
in AIDS patients, 165
Skin
antibacterial effects of antiseptics, 284
Southern blot analysis
variations in typing of *M. tuberculosis*, 749
Spirochaete
novel, from severe virulent ovine foot rot, 1061
Sputum
isolation of *H. influenzae*, 472
Staphylococci
binding of thrombospondin-1, 712
coagulase-negative, 582, 712, 940, 1018
cytoskeletal actin, 35
ecology in oral cavity, 940
heparin-binding protein, 547
hetero-resistance, 1018
protein A, 35
S. aureus, genotyping, 588
S. aureus, hetero-resistance, 1018
S. aureus, increased fusidic acid resistance mutations with salicylate, 104
S. aureus, invasiveness, 35
S. aureus, methicillin-resistant (MRSA), 476, 558, 588, 732, 909, 940, 1018
S. aureus, mupirocin resistance, 909
S. aureus, neutrophil bactericidal dysfunction and ARDS, 49
S. aureus, persistence in a burns unit, 558
S. aureus, selective medium, 476

S. aureus, typing of Brazilian epidemic clone, 732
S. epidermidis, biofilms, 582
S. epidermidis, pathogenesis and epidemiology, 582
Stool antigen assay
detection of *H. pylori* in faeces, 1021
Streptococci
anti-cariogenic properties of tea, 299
group A, 1
S. anginosus, induction of nitric oxide synthesis, 952
S. anginosus, novel antigen, 952
S. intermedius, osteomyelitis and muscle abscess, 480
S. pneumoniae, blood–brain barrier permeability in sepsis, 812
S. pneumoniae, cefotaxime resistance, 173
S. pneumoniae, nasopharyngeal carriage in children, 1095
S. pneumoniae, penicillin resistance, 828
type specificity, 1
Swarming
P. mirabilis super-swarming mutants, 1039

T cells
in *R. aurantiacus*-induced granuloma formation, 688
Tea, anti-cariogenic properties, 299
Teichuronic acids
M. luteus, induction of cytokines, 4
Temperature
in interaction of *H. ducreyi* and epithelial cells, 449
Thromboplastin, tissue
in meningococcal disease, 853
Thrombospondin-1
binding of coagulase-negative staphylococci, 712
Toxins
campylobacters, 1087
cytolethal distending, 860, 1087
exotoxin A of *P. aeruginosa*, 822
Shiga-like, 90
Toxoplasma gondii
comparison of detection methods, 1100
serological markers for toxoplasmosis, 62
Toxoplasmosis, 62, 1100
Transcription factor SP-1, 233
Transforming growth factor-β (TGF-β)
in meningococcal disease, 853, 855
Treponema spp.
novel spirochaete from ovine foot rot, 1061
T. pallidum, genome sequencing, 843
Triclosan
antibacterial effects on skin, 284
Tubal factor infertility, 902
Tuberculosis, 916
skeletal, 355
Tumour necrosis factor-α (TNF-α)
blood–brain barrier permeability in sepsis, 812
induction by *M. luteus* teichuronic acids, 4
in meningococcal disease, 849, 855
Tumour necrosis factor receptor
in meningococcal disease, 852, 855
Type III secretion (TTS) systems, 116

Ultrasound-enhanced latex agglutination assay, 203
Urine
detection of *L. pneumophila* antigens, 509
Urosepsis
pyelonephritogenic *E. coli*, 650

Vaccines
meningococcal, 937
mimotope, 937
peptide-based strategies, 937

Vancomycin
hetero-resistance of *S. aureus*, 1018
resistant enterococci, 695
Vascular endothelial growth factor (VEGF)
production by LPS-stimulated monocytes, 233
Verocytotoxin-producing *E. coli* (VTEC), 135
Vibrio spp.
V. cholerae, antagonism of faecal microbiota, 161
V. cholerae, characterisation of O139 O antigens, 499
V. cholerae, characterisation of rough variants, 268
V. cholerae, comparison of clinical and environmental isolates, 879
V. cholerae, cross-protective antigen, 489
V. cholerae, production of diagnostic antiserum, 499
V. parahaemolyticus, haemolysin-induced chloride secretion, 870
Virulence factors
A. caviae, 303, 313
C. albicans, 743
E. coli, 602
H. alvei, 208
M. tuberculosis, 805
P. alcalifaciens, 29
P. mirabilis, 1039
secretory (EspB), 602
S. enterica serotype Typhimurium, 770
S. epidermidis, 582
type III secretion systems and pathogenicity islands, 116
V. cholerae, 879
Y. pestis, 1015

Water samples
coastal, resistance patterns of enterococci, 1001
Weil's syndrome, 96

Yeasts
comparison of identification methods, 1105
see also specific organisms
Yersinia spp.
Y. enterocolitica, interaction with platelets, 1030
Y. enterocolitica, *she* pathogenicity island, 780
Y. pestis, acid-stable proteins, 979
Y. pestis, fraction I biosynthesis, 969
Y. pestis, modified lipopolysaccharide, 979
Y. pestis, monoclonal antibody, 13
Y. pestis, pLCR-encoded proteins, 13
Y. pestis, virulence factors, 1015
Y. pseudotuberculosis, interaction with platelets, 1030

Zoonosis
L. fainei, 96

INDEX OF AUTHORS FOR VOLUME 50

AALTONEN L-M, AUVINEN E, DILLNER J, LEHTINEN M, PAAVONEN J, RIHKANEN H, VAHERI A. Poor antibody response against human papillomavirus in adult-onset laryngeal papillomatosis, 468
ABEYAMA K *see* SAKUTA *et al.*, 233
ACKERLEY C *see* SAJJAN *et al.*, 535
ADAK G K *see* WILLSHAW *et al.*, 135
ADLER B *see* AL-HASANI *et al.*, 780
AGARWAL P, YADAV R P, UPADHYAY S N. A new method of detection and differentiation of pathogenic from non-pathogenic *Aspergillus* species, 653
AGGARWAL K K *see* RAJIV *et al.*, 916
AHLMAN K *see* AHMED *et al.*, 860
AHLUWALIA M, BRUMMER E, SRIDHAR S, SINGH R, STEVENS D A. Isolation and characterisation of an anticryptococcal protein in human cerebrospinal fluid, 83
AHMAD R *see* BINUKRISHNAN *et al.*, 935
AHMED H J, SVENSSON L A, COPE L D, LATIMER J L, HANSEN E J,
AHLMAN K, BAYAT-TURK J, KLAMER D, LAGERGÅRD T. Prevalence of *cdtABC* genes encoding cytolethal distending toxin among *Haemophilus ducreyi* and *Actinobacillus actinomycetemcomitans* strains, 860
AHRENS P *see* BANG *et al.*, 1087
AKALIN H *see* VAHABOGLU *et al.*, 642
ALA-HOUHALA M *see* JANTUNEN *et al.*, 650
AL-HADDAD A M, UDO E E, MOKADAS E M, SANYAL S C, GRUBB W B. Persistence of a clone of methicillin-resistant *Staphylococcus aureus* in a burns unit, 558
AL-HASANI K, ADLER B, RAJAKUMAR K, SAKELLARIS H. Distribution and structural variation of the *she* pathogenicity island in enteric bacterial pathogens, 780
ALLEN-VERCOE E *see* NAUGHTON *et al.*, 191
ALMEIDA A M P *see* SOBREIRA *et al.*, 29
AMANO K-I *see* MATSUYAMA *et al.*, 865
AMAR C *see* PEDRAZA-DÍAZ S *et al.*, 293
ANDRADE A F B *see* ROCHA-DE-SOUZA *et al.*, 313
ANDREWS N *see* NYE *et al.*, 472, 659
ANNUK H, HYNES S O, HIRMO S, MIKELSAAR M, WADSTRÖM T. Characterisation and differentiation of lactobacilli by lectin typing, 1069
ANTÓNIO V L *see* MARQUES *et al.*, 23
ARBEIT R D *see* MICHAUD *et al.*, 1075
ARBEIT R D *see* VAN SOOLINGEN AND ARBEIT, 749
ARIZA J *see* MARRODAN *et al.*, 663
ARNEZ M *see* RUZIC-SABLJIC *et al.*, 896
ARNOLD C *see* HOOKEY AND ARNOLD, 991
ARNOLD C *see* MORTIMER AND ARNOLD, 393
ARVANITIDOU M, KATSOUYANNOPOULOS V, TSAKRIS A. Antibiotic resistance patterns of enterococci isolated from coastal bathing waters, 1001
ASCANIUS PROJECT COLLABORATIVE GROUP *see* MARCHISIO *et al.*, 1095
ASCENCIO F *see* GUZMAN-MURILLO *et al.*, 320
ASCENCIO F *see* RUIZ-BUSTOS *et al.*, 215
ATTARD L *see* CALZA *et al.*, 480
AUVINEN E *see* AALTONEN *et al.*, 468
AVLAMIS A *see* DEMERTZI *et al.*, 682

BABU C R *see* RAJIV *et al.*, 916
BAGG J *see* SMITH *et al.*, 940
BAIRD A *see* DRUDY *et al.*, 526
BALAKRISHNAN A *see* KUMAR *et al.*, 602
BANG D D, SCHEUTZ F, AHRENS P, PEDERSEN K, BLOM J, MADSEN M. Prevalence of cytolethal distending toxin (*cdt*) genes and CDT production in *Campylobacter* spp. isolated from Danish broilers, 1087
BANNANTINE J P, STABEL J R. Identification of two *Mycobacterium avium* subspecies *paratuberculosis* gene products differentially recognised by sera from rabbits immunised with live mycobacteria but not heat-killed mycobacteria, 795
BARBOSA H S *see* PLOTKOWSKI *et al.*, 183
BARDOCZ S *see* NAUGHTON *et al.*, 191, 1049
BARLOW R E L, COOKE I D, ODUKOYA O, HEATLEY M K, JENKINS J, NARAYANSINGH G, RAMSEWAK S S, ELEY A. The prevalence of *Chlamydia trachomatis* in fresh tissue specimens from patients with ectopic pregnancy or tubal factor infertility as determined by PCR and in-situ hybridisation, 902
BAYAT-TURK J *see* AHMED *et al.*, 860
BEIGHTON D *see* ROBERTS *et al.*, 620
BENARD G *see* JUVENALE *et al.*, 127
BENTO C N O *see* DA SILVA FILHO *et al.*, 261
BERCHE P *see* FERRONI AND BERCHE, 828
BEST A *see* DIBB-FULLER *et al.*, 759
BETTELHEIM K A. Enterohaemorrhagic *Escherichia coli* O157:H7: a red herring?, 201
BETTELHEIM K A *see* MARSHALL *et al.*, 143
BHATTACHARYA S K *see* DUTTA *et al.*, 667
BHATTACHARYA S K *see* MITRA *et al.*, 268
BIAGINI G A *see* SOBANSKI *et al.*, 203
BIANCHINI S *see* PONTIERI *et al.*, 441
BILLING H *see* FREIDANK *et al.*, 223
BINGOL R *see* GÜNDES *et al.*, 1105
BINUKRISHNAN S, HOWSE M, NEAL T, AHMAD R. A case of *Campylobacter jejuni* peritonitis in a patient undergoing peritoneal dialysis, 935
BLANC D *see* GRADY *et al.*, 588
BLOM J *see* BANG *et al.*, 1087
BLOM J *see* PETERSEN *et al.*, 96
BOIRON P *see* DURÁN *et al.*, 101
BOOG C J P *see* RINGROSE *et al.*, 385
BOSE M *see* RAJIV *et al.*, 916
BOTZENHART K *see* HEININGER *et al.*, 243
BOUCHARA J-P *see* CIMON *et al.*, 367
BOUCHARA J-P *see* ZOUHAIR *et al.*, 925
BOUHAOUALA S S *see* BROOK *et al.*, 702
BOYD J *see* SHEPEL *et al.*, 1030
BOYE K *see* PETERSEN *et al.*, 96
BRANDÃO O *see* ZEIDNER *et al.*, 1055
BRAZIER J S *see* URBÁN *et al.*, 1082
BRENNAN P J *see* MARQUES *et al.*, 23
BRETT M S. Emergence of a high-level cefotaxime-resistant *Streptococcus pneumoniae* strain in New Zealand, 173
BRIGANTI E *see* CALZA *et al.*, 480
BROOK I, ELLIOTT T B, HARDING R A, BOUHAOUALA S S, PEACOCK S J, LEDNEY G D, KNUDSON G B. Susceptibility of irradiated mice to *Bacillus anthracis* Sterne by the intratracheal route of infection, 702
BRUCE K D *see* DEMIRKAN *et al.*, 1061
BRUMMER E *see* AHLUWALIA *et al.*, 83

CALZA L, MANFREDI R, BRIGANTI E, ATTARD L, CHIODO F. Iliac osteomyelitis and gluteal muscle abscess caused by *Streptococcus intermedius*, 480
CARACCIOLO C *see* PONTIERI *et al.*, 441
CARDINES R *see* SPIGAGLIA *et al.*, 407
CARION F *see* VAN LOOVEREN *et al.*, 986
CARRUBA G *see* PONTIERI *et al.*, 441
CARTER S D *see* DEMIRKAN *et al.*, 1061
CASAO M A, DÍAZ R, ORDUÑA A, GAMAZO C. Promotion of platelet aggregation by sera from brucellosis patients with antiphosphatidylcholine antibodies, 965
CATTON M G *see* MARSHALL *et al.*, 143
CAUGANT D A *see* VAN LOOVEREN *et al.*, 986
CELLESI C *see* VALASSINA *et al.*, 228
CHABASSE D *see* CIMON *et al.*, 367
CHA J D *see* JUNG *et al.*, 35
CHAE G-T *see* KANG *et al.*, 675
CHAKRABORTY S, GARG P, RAMAMURTHY T, THUNGAPATHRA M, GAUTAM J K, KUMAR C, MAITI S, YAMASAKI S, SHIMADA T, TAKEDA Y, GHOSH A, NAIR G B. Comparison of antibiogram, virulence genes, ribotypes and DNA fingerprints of *Vibrio cholerae* of matching serogroups isolated from hospitalised diarrhoea cases and from the environment during 1997–1998 in Calcutta, India, 879
CHAPELLE S *see* VAN LOOVEREN *et al.*, 986

CHARALAMBOUS B M, FEAVERS I M. Mimotype vaccines, 937
CHATTERJEE A *see* DUTTA *et al.*, 667
CHATTOPADHYAY U K, RASHID M, SUR S K, PAL D. The occurrence of campylobacteriosis in domestic animals and their handlers in and around Calcutta, 933
CHEASTY T *see* WILLSHAW *et al.*, 135
CHEN M-K *see* WANG *et al.*, 277
CHENTHAMARAKSHAN V, KUMUTHA M V, VADIVELU J, PUTHUCHEARY S D. Distribution of immunoglobulin classes and IgG subclasses against a culture filtrate antigen of *Burkholderia pseudomallei* in melioidosis patients, 55
CHIODO F *see* CALZA *et al.*, 480
CHIU C-H, OSTRY A, SPEERT D P. Invasion of murine respiratory epithelial cells *in vivo* by *Burkholderia cepacia*, 594
CHOI B K *see* JUNG *et al.*, 35
CHU M-L *see* WANG *et al.*, 277
CIMON B, SYMOENS F, ZOUHAIR R, CHABASSE D, NOLARD N, DEFONTAINE A, BOUCHARA J-P. Molecular epidemiology of airway colonisation by *Aspergillus fumigatus* in cystic fibrosis patients, 367
CIMON B *see* ZOUHAIR *et al.*, 925
CIMPERMAN J *see* RUZIC-SABLJIC *et al.*, 896
CLAVIJO E *see* MARRODAN *et al.*, 663
COAKLEY W T *see* SOBANSKI *et al.*, 203
COLEMAN D J *see* NYE *et al.*, 659
COLOMBO A V *see* ROCHA-DE-SOUZA *et al.*, 313
COMUÑAS F *see* DURÁN *et al.*, 101
CONRAD A *see* RAUER AND CONRAD, 577
CONTINI C *see* TOGNON *et al.*, 165
COOKE I D *see* BARLOW *et al.*, 902
COOKSON A L *see* WALES *et al.*, 752
COOLES S W *see* RANDALL *et al.*, 919
COOLEY W A *see* DIBB-FULLER *et al.*, 759
COONEY M A, GORRELL R J, PALOMBO E A. Characterisation and phylogenetic analysis of the VP7 proteins of serotype G6 and G8 human rotaviruses, 462
COPE L D *see* AHMED *et al.*, 860
COPPING S J *see* ENGLER *et al.*, 1006
CORACHÁN M *see* VILA *et al.*, 996
COREY M *see* SAJJAN *et al.*, 535
CORSARO D *see* VALASSINA *et al.*, 228
COSKUNKAN F *see* VAHABOGLU *et al.*, 642
COSTA A O *see* PLOTKOWSKI *et al.*, 183
COSTA-DE-OLIVEIRA S *see* PINA-VAZ *et al.*, 375
CRICHTON P B *see* OLD *et al.*, 415
CULTRERA R *see* TOGNON *et al.*, 165
CURRIE C G, McCALLUM K, POXTON I R. Mucosal and systemic antibody responses to the lipopolysaccharide of *Escherichia coli* O157 in health and disease, 345
CUSI M G *see* VALASSINA *et al.*, 228
CUTZ E *see* SAJJAN *et al.*, 535

DALLAPICCOLA B *see* PONTIERI *et al.*, 441
DAM T *see* RAJIV *et al.*, 916
DANGLER C A *see* FOX *et al.*, 421
DANKERT J *see* RINGROSE *et al.*, 385
D'ANTONIO D *see* PONTIERI *et al.*, 441
DA SILVA CARVALHO M C *see* SANTOS SOARES *et al.*, 732
DA SILVA FILHO L V F, LEVI J E, BENTO C N O, RODRIGUES J C, DA SILVA RAMOS S R T. Molecular epidemiology of *Pseudomonas aeruginosa* infections in a cystic fibrosis outpatient clinic, 261
DA SILVA RAMOS S R T *see* DA SILVA FILHO *et al.*, 261
DAVIES S *see* ZADIK *et al.*, 476
DAWSON S *see* WINSTANLEY *et al.*, 255
DE BENTZMANN S *see* PLOTKOWSKI *et al.*, 183
DEFONTAINE A *see* CIMON *et al.*, 367
DEFONTAINE A *see* ZOUHAIR *et al.*, 925
DEI-CAS E *see* NEVEZ *et al.*, 198
DEL NEGRO G M B *see* JUVENALE *et al.*, 127
DELOGU G *see* MASCELLINO *et al.*, 49
DEMERTZI E, PALEPOU M-F I, KAUFMANN M E, AVLAMIS A, WOODFORD N. Characterisation of VanA and VanB elements from glycopeptide-resistant Enterococcus faecium from Greece, 682
DEMIRKAN I, CARTER S D, WINSTANLEY C, BRUCE K D, McNAIR N M, WOODSIDE M, HART C A. Isolation and characterisation of a novel spirochaete from severe virulent ovine foot rot, 1061
DETSIKA M G *see* WINSTANLEY *et al.*, 728
DETTMAR P W *see* MESSAGER *et al.*, 284
DEUNFF J *see* ZOUHAIR *et al.*, 925
DEVDARIANI Z L *see* FEODOROVA AND DEVDARIANI, 13, 969, 979
DEVDARIANI Z L *see* FEODOROVA *et al.*, 499
DEVRIESE L A *see* ROBERTS *et al.*, 620
DEWHIRST F E *see* FOX *et al.*, 421
DIAS R S *see* SILVA *et al.*, 161
DÍAZ R *see* CASAO *et al.*, 965
DIAZ R *see* MARRODAN *et al.*, 663
DIBB-FULLER M P, BEST A, STAGG D A, COOLEY W A, WOODWARD M J. An in-vitro model for studying the interaction of *Escherichia coli* O157:H7 and other enteropathogens with bovine primary cell cultures, 759
DILLNER J *see* AALTONEN *et al.*, 468
DONOGHUE H D, HOLTON J, SPIGELMAN M. PCR primers that can detect low levels of *Mycobacterium leprae* DNA, 177
DÖRING G *see* HEININGER *et al.*, 243
DOWNES J, MUNSON M A, SPRATT D A, KONONEN E, TARKKA E, ROUSIMIES-SOMER H, WADE W G. Characterisation of *Eubacterium*-like strains isolated from oral infections, 947
DRUDY D, O'DONOGHUE D P, BAIRD A, FENELON L, O'FARRELLY C. Flow cytometric analysis of *Clostridium difficile* adherence to human intestinal epithelial cells, 526
DUARTE A J S *see* JUVENALE *et al.*, 127
DUERDEN B I *see* URBÁN *et al.*, 1082
DURÁN E, LÓPEZ L, MARTÍNEZ A, COMUÑAS F, BOIRON P, RUBIO M C. Primary brain abscess with *Nocardia otitidiscaviarum* in an intravenous drug abuser, 101
DUTTA P *see* DUTTA *et al.*, 667
DUTTA S, CHATTERJEE A, DUTTA P, RAJENDRAN K, ROY S, PRAMANIK K C, BHATTACHARYA S K. Sensitivity and performance characteristics of a direct PCR with stool samples in comparison to conventional techniques for diagnosis of *Shigella* and enteroinvasive *Escherichia coli* infection in children with acute diarrhoea in Calcutta, India, 667
DZHAPARIDZE M N *see* FEODOROVA *et al.*, 499

EDWARDS R *see* SÓKI *et al.*, 107
EFSTRATIOU A *see* ENGLER *et al.*, 1006
ELEY A *see* BARLOW *et al.*, 902
ELLIOTT T B *see* BROOK *et al.*, 702
ENGLER K H, KOZLOV R S, COPPING S J, EFSTRATIOU A. International external quality assessment scheme for the laboratory diagnosis of diphtheria, 1006
ESPASA M *see* VILA *et al.*, 996
ESPOSITO S *see* MARCHISIO *et al.*, 1095
EVERETT D *see* GILLESPIE *et al.*, 565

FALLGREN C, UTT M, LJUNGH A. Isolation and characterisation of a 17-kDa staphylococcal heparin- binding protein with broad specificity, 547
FALLON D *see* NYE *et al.*, 472, 659
FEAVERS I M *see* CHARALAMBOUS AND FEAVERS, 937
FELTKAMP T E W *see* RINGROSE *et al.*, 385
FENELON L *see* DRUDY *et al.*, 526
FEODOROVA V A, DEVDARIANI Z L. Expression of acid-stable proteins and modified lipopolysaccharide of *Yersinia pestis* in acidic growth medium, 979
FEODOROVA V A, DEVDARIANI Z L. Immunogeneity and structural organisation of some pLCR-encoded proteins of *Yersinia pestis*, 13
FEODOROVA V A, DEVDARIANI Z L. New genes involved in *Yersinia pestis* fraction I biosynthesis, 969
FEODOROVA V A, GROMOVA O V, DEVDARIANI Z L, DZHAPARIDZE M N, TERYOSHKINA N Y. Immunochemical characterisation of *Vibrio cholerae* O139 O antigens and production of a diagnostic antiserum without absorption, 499
FERREIRA-CARVALHO B T *see* SANTOS SOARES *et al.*, 732
FERRONI A, BERCHE P. Alterations to penicillin-binding proteins 1A, 2B and 2X amongst penicillin-resistant clinical isolates of *Streptococcus pneumoniae* serotype 23F from the nasopharyngeal flora of children, 828
FIGUEIREDO A M S *see* SANTOS SOARES *et al.*, 732
FIKRIG E *see* MAGNARELLI *et al.*, 889
FILIPE A R *see* ZEIDNER *et al.*, 1055
FISCHER A *see* PODSCHUN *et al.*, 208

FISHBAIN S *see* SHARP *et al.*, 152
FLORI P *see* HAFID *et al.*, 1100
FLORQUIN S *see* SCHULTZ *et al.*, 822
FODOR E *see* SÓKI *et al.*, 107
FONSECA A F *see* PINA-VAZ *et al.*, 375
FORSTNER J *see* SAJJAN *et al.*, 535
FORSYTHE S J *see* MANSFIELD AND FORSYTHE, 339
FOX J G, HANDT L, XU S, SHEN Z, DEWHIRST F E, PASTER B J, DANGLER C A, LODGE K, MOTZEL S, KLEIN H. Novel *Helicobacter* species isolated from rhesus monkeys with chronic idiopathic colitis, 421
FREIDANK H M, BILLING H, WIEDMANN-AL-AHMAD M. Influence of iron restriction on *Chlamydia pneumoniae* and *C. trachomatis*, 223
FREITAS A C *see* ROCHA-DE-SOUZA *et al.*, 313
FUJIKAWA T *see* MIYAZAKI *et al.*, 695
FURR P M *see* TAYLOR-ROBINSON AND FURR, 383
FUSSING V *see* NØRSKOV-LAURITSEN *et al.*, 636

GALLEGO L, TOWNER K J. Carriage of class 1 integrons and antibiotic resistance in clinical isolates of *Acinetobacter baumannii* from Northern Spain, 71
GAMAZO C *see* CASAO *et al.*, 965
GARG P *see* CHAKRABORTY *et al.*, 879
GARZELLI C *see* LARI *et al.*, 805
GASCÓN J *see* VILA *et al.*, 996
GASKELL R M *see* WINSTANLEY *et al.*, 255
GASTON J *see* MARSHALL *et al.*, 143
GAUDREAU C *see* MICHAUD *et al.*, 1075
GAUTAM J K *see* CHAKRABORTY *et al.*, 879
GEE B *see* NYE *et al.*, 472, 659
GERN L *see* ZEIDNER *et al.*, 1055
GHOSH A *see* CHAKRABORTY *et al.*, 879
GIARDINA A *see* MASCELLINO *et al.*, 49
GIBB A P *see* SHEPEL *et al.*, 1030
GILLESPIE S H, MORRISSEY I, EVERETT D. A comparison of the bactericidal activity of quinolone antibiotics in a *Mycobacterium fortuitum* model, 565
GIRONI S *see* MARCHISIO *et al.*, 1095
GLENDINNING K J *see* WINSTANLEY *et al.*, 728
GODDARD P A *see* MESSAGER *et al.*, 284
GOOSSENS H *see* VAN LOOVEREN *et al.*, 986
GOPALAKRISHNAKONE P *see* SHANG *et al.*, 655
GORRELL R J *see* COONEY *et al.*, 462
GRADY R, BLANC D, HAUSER P, STANLEY J. Genotyping of European isolates of methicillin-resistant *Staphylococcus aureus* by fluorescent amplified-fragment length polymorphism analysis (FAFLP) and pulsed-field gel electrophoresis (PFGE) typing, 588
GRANT G *see* NAUGHTON *et al.*, 191, 1049
GRAY G C *see* LE *et al.*, 571
GREGORY J *see* MARSHALL *et al.*, 143
GRIFFITH J M *see* MARSHALL *et al.*, 143
GROMOVA O V *see* FEODOROVA *et al.*, 499
GRUBB W B *see* AL-HADDAD *et al.*, 558
GULENC S *see* GÜNDES *et al.*, 1105
GÜNDES S G, GULENC S, BINGOL R. Comparative performance of Fungichrom I, Candifast and API 20C Aux systems in the identification of clinically significant yeasts, 1105
GUNESEKERE I C *see* MARSHALL *et al.*, 143
GUSTAFSON J E *see* PRICE AND GUSTAFSON, 104
GUSZCZYNSKA E *see* KRZYMINSKA *et al.*, 303
GUTH B E C *see* SOBREIRA *et al.*, 29
GUYOT K *see* NEVEZ *et al.*, 198
GUZMAN-MURILLO M A, RUIZ-BUSTOS E, HO B, ASCENCIO F. Involvement of the heparan sulphate-binding proteins of *Helicobacter pylori* in its adherence to HeLa S3 and Kato III cell lines, 320

HAAS C J *see* ZINK *et al.*, 355
HACKETT S J, THOMSON A P J, HART C A. Cytokines, chemokines and other effector molecules involved in meningococcal disease, 847
HAFID J, FLORI P, RABERIN H, TRAN MANH SUNG R. Comparison of PCR, capture ELISA and immunoblotting for detection of *Toxoplasma gondii* in infected mice, 1100
HAIGH R *see* KUMAR *et al.*, 602
HALLET J-N *see* ZOUHAIR *et al.*, 925
HAMILTON-MILLER J M T. Anti-cariogenic properties of tea (*Camellia sinensis*), 299
HANDT L *see* FOX *et al.*, 421
HANSEN E J *see* AHMED *et al.*, 860
HARDING R A *see* BROOK *et al.*, 702
HARRISON T G *see* HELBIG *et al.*, 509
HART C A *see* DEMIRKAN *et al.*, 1061
HART C A *see* HACKETT *et al.*, 847
HART C A *see* WINSTANLEY AND HART, 111
HART C A *see* WINSTANLEY *et al.*, 255, 728
HASE S *see* MONODANE *et al.*, 4
HASHIMOTO M *see* MATSUYAMA *et al.*, 865
HAUSER P *see* GRADY *et al.*, 588
HAYASHI S *see* MATSUYAMA *et al.*, 865
HAYES C M *see* WALES *et al.*, 752
HEATLEY M K *see* BARLOW *et al.*, 902
HEDEGAARD J *see* NØRSKOV-LAURITSEN *et al.*, 636
HEININGER A, ULRICH M, PRIEBE G, UNERTL K, MÜLLER-SCHAUENBURG A, BOTZENHART K, DÖRING G. The effect of human serum DNAases on the ability to detect antibiotic- killed *Escherichia coli* in blood by PCR, 243
HELBIG J H, ULDUM S A, LÜCK P C, HARRISON T G. Detection of *Legionella pneumophila* antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax *Legionella* Urinary Enzyme Immunoassay (EIA) and Biotest *Legionella* Urin Antigen EIA, 509
HILTON A C *see* HOPKINS AND HILTON, 90
HIRAI Y *see* MATSUYAMA *et al.*, 865
HIRATA R *see* ROCHA-DE-SOUZA *et al.*, 313
HIRMO S *see* ANNUK *et al.*, 1069
HIRMO S *see* WANG *et al.*, 430
HIRST R *see* LEAKEY *et al.*, 787
HO B *see* GUZMAN-MURILLO *et al.*, 320
HO M *see* WANG *et al.*, 277
HO S-W *see* LIAW *et al.*, 1039
HOGG G G *see* MARSHALL *et al.*, 143
HOLTON J *see* DONOGHUE *et al.*, 177
HOMER K A *see* ROBERTS *et al.*, 620
HONDA T *see* TAKAHASHI *et al.*, 870
HOOKEY J V, ARNOLD C. A comparison of multilocus sequence typing and fluorescent fragment-length polymorphism analysis genotyping of clone complex and other strains of *Neisseria meningitidis*, 991
HOPKINS K L, HILTON A C. Restriction endonuclease analysis of RAPD-PCR amplicons derived from Shiga-like toxin- producing *Escherichia coli* O157 isolates, 90
HOWE S *see* NYE *et al.*, 472
HOWSE M *see* BINUKRISHNAN *et al.*, 935
HSU H P *see* TSAO *et al.*, 812
HUMAR A *see* SAJJAN *et al.*, 535
HUMPHREYS H *see* O'GARA AND HUMPHREYS, 582
HYNES S O *see* ANNUK *et al.*, 1069

IACCHERI L *see* TOGNON *et al.*, 165
IHALIN R, LOIMARANTA V, LENANDER-LUMIKARI M, TENOVUO J. The sensitivity of *Porphyromonas gingivalis* and *Fusobacterium nucleatum* to different (pseudo)halide- peroxidase combinations compared with mutans streptococci, 42
IIDA T *see* TAKAHASHI *et al.*, 870
IJDO J W *see* MAGNARELLI *et al.*, 889
IVERSEN A M *see* PEDRAZA-DÍAZ S *et al.*, 293
IWAKURA Y *see* YOSHIDA *et al.*, 959

JACKSON M S *see* SMITH *et al.*, 940
JACOB L E *see* UDO *et al.*, 909
JANTUNEN M E, SAXÉN H, LUKINMAA S, ALA-HOUHALA M, SIITONEN A. Genomic identity of pyelonephritogenic *Escherichia coli* isolated from blood, urine and faeces of children with urosepsis, 650
JANUSCHKE E *see* SCHALLER *et al.*, 743
JENKINS J *see* BARLOW *et al.*, 902
JENKS P J. *Helicobacter pylori*: towards new therapeutic targets, 485
JIMÉNEZ DE ANTA M T *see* VILA *et al.*, 996
JOUSIMIES-SOMER H *see* DOWNES *et al.*, 947
JUNG K Y, CHA J D, LEE S H, WOO W H, LIM D S, CHOI B K, KIM K J. Involvement of staphylococcal protein A and cytoskeletal actin in *Staphylococcus aureus* invasion of cultured human oral epithelial cells, 35

JUVENALE M, DEL NEGRO G M B, DUARTE A J S, BENARD G. Antibody isotypes to a *Paracoccidioides brasiliensis* somatic antigen in sub-acute and chronic form paracoccidioidomycosis, 127

KABIR S. Detection of *Helicobacter pylori* in faeces by culture, PCR and enzyme immunoassay, 1021
KANG T-J, YOU J-C, CHAE G-T. Identification of catalase- like activity from *Mycobacterium leprae* and the relationship between catalase and isonicotinic acid hydrazide (INH), 675
KARASAWA T *see* KATO *et al.*, 720
KATO H, KITA H, KARASAWA T, MAEGAWA T, KOINO Y, TAKAKUWA H, SAIKAI T, KOBAYASHI K, YAMAGISHI T, NAKAMURA S. Colonisation and transmission of *Clostridium difficile* in healthy individuals examined by PCR ribotyping and pulsed-field gel electrophoresis, 720
KATSOUYANNOPOULOS V *see* ARVANITIDOU *et al.*, 1001
KATTI M K. Plasmids of mycobacteria, 575
KAUFMANN M E *see* DEMERTZI *et al.*, 682
KAWABATA Y *see* MONODANE *et al.*, 4
KIM K J *see* JUNG *et al.*, 35
KIMURA S *see* SASAKI *et al.*, 952
KIRIKAE F *see* MATSUYAMA *et al.*, 865
KIRIKAE T *see* MATSUYAMA *et al.*, 865
KITA H *see* KATO *et al.*, 720
KLAMER D *see* AHMED *et al.*, 860
KLEIN H *see* FOX *et al.*, 421
KNUDSON G B *see* BROOK *et al.*, 702
KOBAYASHI I *see* MIYAZAKI *et al.*, 695
KOBAYASHI K *see* KATO *et al.*, 720
KOBAYASHI M *see* SASAKI *et al.*, 952
KOCAGOZ S *see* VAHABOGLU *et al.*, 642
KOCAZEYBEK B *see* VAHABOGLU *et al.*, 642
KOGA T *see* SAKUTA *et al.*, 233
KOHANAWA M *see* YIMIN *et al.*, 688
KOINO Y *see* KATO *et al.*, 720
KOKSAL I *see* VAHABOGLU *et al.*, 642
KONONEN E *see* DOWNES *et al.*, 947
KONTOYIANNIS D P, TARRAND J, PRINCE R, SAMONIS G, ROLSTON K V R. Effect of fluconazole on agar invasion by *Candida albicans*, 78
KORTEN V *see* VAHABOGLU *et al.*, 642
KORTING H C *see* SCHALLER *et al.*, 743
KÖSTERS K, RIFFELMANN M, WIRSING VON KÖNIG C H. Evaluation of a real-time PCR assay for detection of *Bordetella pertussis* and *B. parapertussis* in clinical samples, 436
KOZLOV R S *see* ENGLER *et al.*, 1006
KROGFELT K A *see* PETERSEN *et al.*, 96
KRZYMINSKA S, MOKRACKA J, LAGANOWSKA M, WLODARCZAK K, GUSZCZYNSKA E, LISZKOWSKA J, POPKOWSKA E, LIMA I, LEMANSKA I, WENDT M. Enhancement of the virulence of *Aeromonas caviae* diarrhoeal strains by serial passages in mice, 303
KUBOTA T *see* MATSUYAMA *et al.*, 865
KUMAR C *see* CHAKRABORTY *et al.*, 879
KUMAR S, RAY P, SINGH H, KUMAR GANGULY N. Immunogenicity and protective role of an IgA reactive 31-kDa antigen of *Vibrio cholerae* O139, 489
KUMAR S *see* RAJIV *et al.*, 916
KUMAR S S, SANKARAN K, HAIGH R, WILLIAMS P H, BALAKRISHNAN A. Cytopathic effects of outer-membrane preparations of enteropathogenic *Escherichia coli* and co-expression of maltoporin with secretory virulence factor, EspB, 602
KUMAR GANGULY N *see* KUMAR *et al.*, 489
KUMUTHA M V *see* CHENTHAMARAKSHAN *et al.*, 55

LA BROOY J *see* LEAKEY *et al.*, 787
LAGANOWSKA M *see* KRZYMINSKA *et al.*, 303
LAGERGÅRD T *see* AHMED *et al.*, 860
LAI H-C *see* LIAW *et al.*, 1039
LARI N, RINDI L, GARZELLI C. Identification of one insertion site of IS*6110* in *Mycobacterium tuberculosis* H37Ra and analysis of the RvD2 deletion in *M. tuberculosis* clinical isolates, 805
LATIMER J L *see* AHMED *et al.*, 860
LE C T, GRAY G C, PODDAR S K. A modified rapid method of nucleic acid isolation from suspension of matured virus: applied in restriction analysis of DNA from an adenovirus prototype strain and a patient isolate, 571
LEAKEY A, HIRST R, LA BROOY J. A low molecular weight factor is a significant mediator of non-opsonic neutrophil activation by *Helicobacter pylori*, 787
LEAL N C *see* SOBREIRA *et al.*, 29
LEBLEBICIOGLU H *see* VAHABOGLU *et al.*, 642
LEDNEY G D *see* BROOK *et al.*, 702
LEE M A *see* SHANG *et al.*, 655
LEE S H *see* JUNG *et al.*, 35
LEHTINEN M *see* AALTONEN *et al.*, 468
LEI H Y *see* TSAO *et al.*, 812
LEMANSKA I *see* KRZYMINSKA *et al.*, 303
LENANDER-LUMIKARI M *see* IHALIN *et al.*, 42
LENNON A *see* RIGGIO *et al.*, 249
LEONG R *see* MITCHELL *et al.*, 627
LEUNG P K-L *see* WOO *et al.*, 330
LEVI J E *see* DA SILVA FILHO *et al.*, 261
LEVY S A *see* MAGNARELLI *et al.*, 889
LI D-Q *see* YANAGISAWA *et al.*, 712
LIAW S-J, LAI H-C, HO S-W, LUH K-T, WANG W-B. Characterisation of *p*-nitrophenylglycerol-resistant *Proteus mirabilis* super-swarming mutants, 1039
LIEB K *see* STAEHELI AND LIEB, 579
LIGHTFOOT D *see* MARSHALL *et al.*, 143
LIM D S *see* JUNG *et al.*, 35
LIMA I *see* KRZYMINSKA *et al.*, 303
LIN F M *see* WANG *et al.*, 277
LISZKOWSKA J *see* KRZYMINSKA *et al.*, 303
LIU C C *see* TSAO *et al.*, 812
LJUNGH A *see* FALLGREN *et al.*, 547
LJUNGH A *see* YANAGISAWA *et al.*, 712
LODGE K *see* FOX *et al.*, 421
LOIMARANTA V *see* IHALIN *et al.*, 42
LÓPEZ L *see* DURÁN *et al.*, 101
LOTRIC-FURLAN S *see* RUZIC-SABLJIC *et al.*, 896
LÜCK P C *see* HELBIG *et al.*, 509
LUH K-T *see* LIAW *et al.*, 1039
LUIDER J *see* SHEPEL *et al.*, 1030
LUKINMAA S *see* JANTUNEN *et al.*, 650

McBAIN A J, MACFARLANE G T. Modulation of genotoxic enzyme activities by non-digestible oligosaccharide metabolism in in-vitro human gut bacterial ecosystems, 833
McCALLUM K *see* CURRIE *et al.*, 345
MACFARLANE G T *see* McBAIN AND MACFARLANE, 833
MACFARLANE G T *see* SHARP *et al.*, 152
McLAUCHLIN J *see* PEDRAZA-DÍAZ S *et al.*, 293
McNAIR N M *see* DEMIRKAN *et al.*, 1061
MADSEN M *see* BANG *et al.*, 1087
MAEGAWA T *see* KATO *et al.*, 720
MAGALHÃES M *see* SOBREIRA *et al.*, 29
MAGEE J T, FOX J D, STUBBS S L J. Cashing in your chips: speculation on the future of diagnostic laboratories in the era of DNA chips, 111
MAGNARELLI L A, LEVY S A, IJDO J W, WU C, PADULA S J, FIKRIG E. Reactivity of dog sera to whole-cell or recombinant antigens of *Borrelia burgdorferi* by ELISA and immunoblot analysis, 889
MAILLARD J-Y *see* MESSAGER *et al.*, 284
MAITI S *see* CHAKRABORTY *et al.*, 879
MAKAKOLE S C, STURM A W. The effect of temperature on the interaction of *Haemophilus ducreyi* with human epithelial cells, 449
MANEERAT Y *see* UBOL *et al.*, 238
MANFREDI R *see* CALZA *et al.*, 480
MANNELLI S *see* MARCHISIO *et al.*, 1095
MANSFIELD L P, FORSYTHE S J. Demonstration of the Rb_1 lipopolysaccharide core structure in *Salmonella* strains with the monoclonal antibody M105, 339
MARASPIN V *see* RUZIC-SABLJIC *et al.*, 896
MARCHISIO P, GIRONI S, ESPOSITO S, SCHITO G C, MANNELLI S, PRINCIPI N, ASCANIUS PROJECT COLLABORATIVE GROUP. Seasonal variations in nasopharyngeal carriage of respiratory pathogens in healthy Italian children attending day-care centres or schools, 1095
MARQUES M A M, ANTÔNIO V L, SARNO E N, BRENNAN P J, PESSOLANI M C V. Binding of α2-laminins by pathogenic and non-pathogenic mycobacteria and adherence to Schwann cells, 23

MARRODAN T, NENOVA-POLIAKOVA R, RUBIO M, ARIZA J, CLAVIJO E, SMITS H L, DIAZ R. Evaluation of three methods to measure anti-*Brucella* IgM antibodies and interference of IgA in the interpretation of mercaptan-based tests, 663
MARSHALL J A, YUEN L K W, CATTON M G, GUNESEKERE I C, WRIGHT P J, BETTELHEIM K A, GRIFFITH J M, LIGHTFOOT D, HOGG G G, GREGORY J, WILBY R, GASTON J. Multiple outbreaks of Norwalk-like virus gastroenteritis associated with a Mediterranean-style restaurant, 143
MARTÍNEZ A *see* DURÁN *et al.*, 101
MARTÍNEZ A J, VISVESVARA G S. *Balamuthia mandrillaris* infection, 205
MARTINEZ-DE-OLIVEIRA J *see* PINA-VAZ *et al.*, 375
MARTINI F *see* TOGNON *et al.*, 165
MARUYAMA I *see* SAKUTA *et al.*, 233
MASCELLINO M T, DELOGU G, PELAIA M R, PONZO R, PARRINELLO R, GIARDINA A. Reduced bactericidal activity against *Staphylococcus aureus* and *Pseudomonas aeruginosa* of blood neutrophils from patients with early adult respiratory distress syndrome, 49
MASON C *see* ZADIK *et al.*, 476
MASTRANTONIO P *see* SPIGAGLIA *et al.*, 407
MATHER H *see* OLD *et al.*, 415
MATHEW B *see* UDO *et al.*, 909
MATSUMOTO T *see* MIYAZAKI *et al.*, 695
MATSUMOTO T *see* YOSHIDA *et al.*, 456, 959
MATSUSHITA K *see* SAKUTA *et al.*, 233
MATSUYAMA N, KIRIKAE T, KIRIKAE F, HASHIMOTO M, AMANO K-I, HAYASHI S, HIRAI Y, KUBOTA T, NAKANO M. Non-standard biological activities of lipopolysaccharide from *Helicobacter pylori*, 865
MATTOS-GUARALDI A L *see* ROCHA-DE-SOUZA *et al.*, 313
MENARD S *see* MICHAUD *et al.*, 1075
MENOZZI M G *see* SPIGAGLIA *et al.*, 407
MESSAGER S, GODDARD P A, DETTMAR P W, MAILLARD J-Y. Determination of the antibacterial efficacy of several antiseptics tested on skin by an 'ex-vivo' test, 284
MESSER S *see* NYE *et al.*, 472, 659
MICHAUD S, MENARD S, GAUDREAU C, ARBEIT R D. Comparison of *Sma*I-defined genotypes of *Campylobacter jejuni* examined by *Kpn*I: a population-based study, 1075
MIGLIORINI L *see* VALASSINA *et al.*, 228
MIKELSAAR M *see* ANNUK *et al.*, 1069
MILLER R D *see* SAHNEY *et al.*, 517
MINAGAWA T *see* YIMIN *et al.*, 688
MITCHELL L A, LEONG R, ROSENKE K A. Lymphocyte recognition of human parvovirus B19 non-structural (NS1) protein: associations with occurrence of acute and chronic arthropathy?, 627
MITRA R K, NANDY R K, RAMAMURTHY T, BHATTACHARYA S K, YAMASAKI S, SHIMADA T, TAKEDA Y, NAIR GB. Molecular characterisation of rough variants of *Vibrio cholerae* isolated from hospitalised patients with diarrhoea, 268
MIYAZAKI S, FUJIKAWA T, KOBAYASHI I, MATSUMOTO T, TATEDA K, YAMAGUCHI K. Development of systemic bacteraemia after oral inoculation of vancomycin-resistant enterococci in mice, 695
MOKADAS E M *see* AL-HADDAD *et al.*, 558
MOKRACKA J *see* KRZYMINSKA *et al.*, 303
MONODANE T, KAWABATA Y, YANG S, HASE S, TAKADA H. Induction of necrosis factor-α and interleukin-6 in mice *in vivo* and in murine peritoneal macrophages and human whole blood cells *in vitro* by *Micrococcus luteus* teichuronic acids, 4
MONTEIRO-LEAL L H *see* ROCHA-DE-SOUZA *et al.*, 313
MOOCHHALA S *see* SHANG *et al.*, 655
MORANDI V *see* PLOTKOWSKI *et al.*, 183
MORRISSEY I *see* GILLESPIE *et al.*, 565
MORTENSEN K K *see* NØRSKOV-LAURITSEN *et al.*, 636
MORTIMER P, ARNOLD C. FAFLP: last word in microbial genotyping?, 393
MOTANI R *see* SAKUTA *et al.*, 233
MOTZEL S *see* FOX *et al.*, 421
MUIJSERS A O *see* RINGROSE *et al.*, 385
MÜLLER-SCHAUENBURG A *see* HEININGER *et al.*, 243
MUNSON M A *see* DOWNES *et al.*, 947

NADER H B *see* PLOTKOWSKI *et al.*, 183
NAGAOKA S *see* SAKUTA *et al.*, 233
NAGY E *see* SÓKI *et al.*, 107
NAGY E *see* URBÁN *et al.*, 1082
NAIM R *see* TAKAHASHI *et al.*, 870
NAIR G B *see* CHAKRABORTY *et al.*, 879
NAIR G B *see* MITRA *et al.*, 268
NAKAMURA S *see* KATO *et al.*, 720
NAKANO M *see* MATSUYAMA *et al.*, 865
NANDY R K *see* MITRA *et al.*, 268
NARAYANSINGH G *see* BARLOW *et al.*, 902
NAUGHTON P J, GRANT G, BARDOCZ S, ALLEN-VERCOE E, WOODWARD M J, PUSZTAI A. Expression of type 1 fimbriae (SEF 21) of *Salmonella enterica* serotype Enteritidis in the early colonisation of the rat intestine, 191
NAUGHTON P J, GRANT G, SOJKA M, BARDOCZ S, THORNS C J, PUSZTAI A. Survival and distribution of cell-free SEF 21 of *Salmonella enterica* serovar Enteritidis in the stomach and various compartments of the rat gastrointestinal tract *in vivo*, 1049
NAYKAYA Y *see* TAKAHASHI *et al.*, 870
NEAL T *see* BINUKRISHNAN *et al.*, 935
NENOVA-POLIAKOVA R *see* MARRODAN *et al.*, 663
NERLICH A G *see* ZINK *et al.*, 355
NEVEZ G, GUYOT K, TOTET A, RACCURT C, DEI-CAS E. Pulmonary colonisation with *Pneumocystis carinii* in an immunosuppressed HIV-negative patient: detection and typing of the fungus by PCR, 198
NICOLI J R *see* SILVA *et al.*, 161
NOLARD N *see* CIMON *et al.*, 367
NORAZMI M N. Possible mechanism for the enhanced lethality of an interleukin-4-expressing mousepox virus, 936
NØRSKOV-LAURITSEN N, SANDVANG D, HEDEGAARD J, FUSSING V, MORTENSEN K K, SPERLING-PETERSEN H U, SCHØNHEYDER H C. Clonal origin of aminoglycoside-resistant *Citrobacter freundii* isolates in a Danish county, 636
NOVELLI G *see* PONTIERI *et al.*, 441
NÚNCIO M S *see* ZEIDNER *et al.*, 1055
NYE K J, FALLON D, GEE B, HOWE S, MESSER S, TURNER T, WARREN R E, ANDREWS N. A comparison of the performance of bacitracin-incorporated chocolate blood agar with chocolate blood agar plus a bacitracin disk in the isolation of *Haemophilus influenzae* from sputum, 472
NYE K J, TURNER T, COLEMAN D J, FALLON D, GEE B, MESSER S, WARREN R E, ANDREWS N. A comparison of the isolation rates of *Salmonella* and thermophilic *Campylobacter* species after direct inoculation of media with a dilute faecal suspension and undiluted faecal material, 659

O'BRIEN S J *see* WILLSHAW *et al.*, 135
OCHOA J L *see* RUIZ-BUSTOS *et al.*, 215
O'DONOGHUE D P *see* DRUDY *et al.*, 526
ODUKOYA O *see* BARLOW *et al.*, 902
O'FARRELLY C *see* DRUDY *et al.*, 526
O'GARA J P, HUMPHREYS H. *Staphylococcus epidermidis* biofilms: importance and implications, 582
OHARA-NEMOTO Y *see* SASAKI *et al.*, 952
OLD D C, CRICHTON P B, TAYLOR A, MATHER H. An attempt to identify the evolutionary origin of a novel serotype of *Salmonella enterica* isolated from harbour porpoises, 415
OLLIVIER C *see* ZOUHAIR *et al.*, 925
ORDUÑA A *see* CASAO *et al.*, 965
OSTRY A *see* CHIU *et al.*, 594
OYAMA T *see* SAKUTA *et al.*, 233
OYSTON P, Plague virulence, 1015
OZINEL M A *see* VAHABOGLU *et al.*, 642
OZTURK R *see* VAHABOGLU *et al.*, 642

PAAVONEN J *see* AALTONEN *et al.*, 468
PADULA S J *see* MAGNARELLI *et al.*, 889
PAL D *see* CHATTOPADHYAY *et al.*, 933
PALEPOU M-F I *see* DEMERTZI *et al.*, 682
PALOMBO E A *see* COONEY *et al.*, 462
PANNEKOEK Y *see* RINGROSE *et al.*, 385
PARKER M T. Winston R. Maxted and the type specificity of group A streptococci, 1
PARRINELLO R *see* MASCELLINO *et al.*, 49
PARSONS Y N *see* WINSTANLEY *et al.*, 728
PASTER B J *see* FOX *et al.*, 421
PEACOCK S J *see* BROOK *et al.*, 702
PEARSON G R *see* WALES *et al.*, 752
PEDERSEN K *see* BANG *et al.*, 1087

PEDRAZA-DÍAZ S, AMAR C, IVERSEN A M, STANLEY P J, McLAUCHLIN J. Unusual *Cryptosporidium* species recovered from human faeces: first description of *Cryptosporidium felis* and *Cryptosporidium* 'dog type' from patients in England, 293
PELAIA M R *see* MASCELLINO *et al.*, 49
PESSOLANI M C V *see* MARQUES *et al.*, 23
PETERSEN A M, BOYE K, BLOM J, SCHLICHTING P, KROGFELT K A. First isolation of *Leptospira fainei* serovar Hurstbridge from two human patients with Weil's syndrome, 96
PHILPOTT-HOWARD J *see* ROBERTS *et al.*, 620
PIESMAN J *see* ZEIDNER *et al.*, 1055
PINA-VAZ C, SANSONETTY F, RODRIGUES A G, COSTA-DE-OLIVEIRA S, MARTINEZ-DE-OLIVEIRA J, FONSECA A F. Susceptibility to fluconazole of *Candida* clinical isolates determined by FUN-1 staining with flow cytometry and epifluorescence microscopy, 375
PLOTKOWSKI M C, COSTA A O, MORANDI V, BARBOSA H S, NADER H B, DE BENTZMANN S, PUCHELLE E. Role of heparan sulphate proteoglycans as potential receptors for non-piliated *Pseudomonas aeruginosa* adherence to non-polarised airway epithelial cells, 183
PODDAR S K *see* LE *et al.*, 571
PODSCHUN R, FISCHER A, ULLMANN U. Characterisation of *Hafnia alvei* isolates from human clinical extra- intestinal specimens: haemagglutinins, serum resistance and siderophore synthesis, 208
PONTIERI E, CARACCIOLO C, BIANCHINI S, D'ANTONIO D, NOVELLI G, DALLAPICCOLA B, CARRUBA G. Single primer pair for PCR identification of *Candida parapsilosis* group I isolates, 441
PONZO R *see* MASCELLINO *et al.*, 49
POPKOWSKA E *see* KRZYMINSKA *et al.*, 303
POXTON I R *see* CURRIE *et al.*, 345
PRAMANIK K C *see* DUTTA *et al.*, 667
PREVIATO J O *see* ROCHA-DE-SOUZA *et al.*, 313
PRICE C T D, GUSTAFSON J E. Increases in the mutation frequency at which fusidic acid-resistant *Staphylococcus aureus* arise with salicylate, 104
PRIEBE G *see* HEININGER *et al.*, 243
PRINCE R *see* KONTOYIANNIS *et al.*, 78
PRINCIPI N *see* MARCHISIO *et al.*, 1095
PUCHELLE E *see* PLOTKOWSKI *et al.*, 183
PUJOL M *see* VILA *et al.*, 996
PUSZTAI A *see* NAUGHTON *et al.*, 191, 1049
PUTHUCHEARY S D *see* CHENTHAMARAKSHAN *et al.*, 55

RABERIN H *see* HAFID *et al.*, 1100
RACCURT C *see* NEVEZ *et al.*, 198
RAJAKUMAR K *see* AL-HASANI *et al.*, 780
RAJENDRAN K *see* DUTTA *et al.*, 667
RAJIV J, DAM T, KUMAR S, BOSE M, AGGARWAL K K, BABU C R. Inhibition of the in-vitro growth of *Mycobacterium tuberculosis* by a phytosiderophore, 916
RAMAMURTHY T *see* CHAKRABORTY *et al.*, 879
RAMAMURTHY T *see* MITRA *et al.*, 268
RAMIREZ J A *see* SAHNEY *et al.*, 517
RAMSEWAK S S *see* BARLOW *et al.*, 902
RANDALL L P, COOLES S W, SAYERS A R, WOODWARD M J. Association between cyclohexane resistance in *Salmonella* of different serovars and increased resistance to multiple antibiotics, disinfectants and dyes, 919
RANDALL L P, WOODWARD M J. Role of the *mar* locus in virulence of *Salmonella enterica* serovar Typhimurium DT104 in chickens, 770
RASHID M *see* CHATTOPADHYAY *et al.*, 933
RATH P-M, SCHMIDT D. Gellan gum as a suitable gelling agent in microbiological media for PCR applications, 108
RAUER S, CONRAD A. Competitive inhibition ELISA for the detection of *Borrelia burgdorferi* antigens – failure to detect antigen in the cerebrospinal fluid from patients with neuroborreliosis, 577
RAY P *see* KUMAR *et al.*, 489
REISCHL U *see* ZINK *et al.*, 355
RIFFELMANN M *see* KÖSTERS *et al.*, 436
RIGGIO M P, LENNON A, SMITH A. Detection of *Peptostreptococcus micros* DNA in clinical samples by PCR, 249
RIHKANEN H *see* AALTONEN *et al.*, 468
RIJNEVELD A W *see* SCHULTZ *et al.*, 822
RINDER H. Hetero-resistance: an under-recognised confounder in diagnosis and therapy?, 1018
RINDI L *see* LARI *et al.*, 805
RINGROSE J H, MUIJSERS A O, PANNEKOEK Y, YARD B A, BOOG C J P, VAN ALPHEN L, DANKERT J, FELTKAMP T E W. Influence of infection of cells with bacteria associated with reactive arthritis on the peptide repertoire presented by HLA-B27, 385
ROBERTS G, HOMER K A, TARELLI E, PHILPOTT-HOWARD J, DEVRIESE L A, BEIGHTON D. Distribution of endo-β-N-acetylglucosaminidase amongst enterococci, 620
ROCHA R J *see* SUZUKI *et al.*, 62
ROCHA-DE-SOUZA C M, COLOMBO A V, HIRATA R, MATTOS-GUARALDI A L, MONTEIRO-LEAL L H, PREVIATO J O, FREITAS A C, ANDRADE A F B. Identification of a 43-kDa outer-membrane protein as an adhesin in *Aeromonas caviae*, 313
RODRIGUES A G *see* PINA-VAZ *et al.*, 375
RODRIGUES J C *see* DA SILVA FILHO *et al.*, 261
ROE J M *see* WALES *et al.*, 752
ROLSTON K V R *see* KONTOYIANNIS *et al.*, 78
ROSÁRIO NUNES M DO *see* SANTOS SOARES *et al.*, 732
ROSENKE K A *see* MITCHELL *et al.*, 627
ROSSI C L *see* SUZUKI *et al.*, 62
ROSSI S *see* SPIGAGLIA *et al.*, 407
ROY S *see* DUTTA *et al.*, 667
RUBIO M *see* MARRODAN *et al.*, 663
RUBIO M C *see* DURÁN *et al.*, 101
RUIZ J *see* VILA *et al.*, 996 RUIZ-BUSTOS E, OCHOA J L, WADSTRÖM T, ASCENCIO F. Isolation and characterisation of putative adhesins from *Helicobacter pylori* with affinity for heparan sulphate proteoglycan, 215
RUIZ-BUSTOS E *see* GUZMAN-MURILLO *et al.*, 320
RUZIC-SABLJIC E, ARNEZ M, LOTRIC-FURLAN S, MARASPIN V, CIMPERMAN J, STRLE F. Genotypic and phenotypic characterisation of *Borrelia burgdorferi sensu lato* strains isolated from human blood, 896

SAHIN N *see* VAHABOGLU *et al.*, 642
SAHNEY N N, SUMMERSGILL J T, RAMIREZ J A, MILLER R D. Inhibition of oxidative burst and chemotaxis in human phagocytes by *Legionella pneumophila* zinc metalloprotease, 517
SAIKAI T *see* KATO *et al.*, 720
SAJJAN U, COREY M, HUMAR A, TULLIS E, CUTZ E, ACKERLEY C, FORSTNER J. Immunolocalisation of *Burkholderia cepacia* in the lungs of cystic fibrosis patients, 535
SAKELLARIS H *see* AL-HASANI *et al.*, 780
SAKUTA T, MATSUSHITA K, YAMAGUCHI N, OYAMA T, MOTANI R, KOGA T, NAGAOKA S, ABEYAMA K, MARUYAMA I, TAKADA H, TORII M. Enhanced production of vascular endothelial growth factor by human monocytic cells stimulated with endotoxin through transcription factor SP-1, 233
SAMONIS G *see* KONTOYIANNIS *et al.*, 78
SANDVANG D *see* NØRSKOV-LAURITSEN *et al.*, 636
SANI G *see* VALASSINA *et al.*, 228
SANKARAN K *see* KUMAR *et al.*, 602
SANSONETTY F *see* PINA-VAZ *et al.*, 375
SANSONI A *see* VALASSINA *et al.*, 228
SANTOS SOARES M J DOS, TEIXEIRA L A, ROSÁRIO NUNES M DO, DA SILVA CARVALHO M C, FERREIRA-CARVALHO B T, FIGUEIREDO A M S. Analysis of different molecular methods for typing methicillin-resistant *Staphylococcus aureus* isolates belonging to the Brazilian epidemic clone, 732
SANYAL S C *see* AL-HADDAD *et al.*, 558
SARNO E N *see* MARQUES *et al.*, 23
SASAKI M, OHARA-NEMOTO Y, TAJIKA S, KOBAYASHI M, YAMAURA C, KIMURA S. Antigenic characterisation of a novel *Streptococcus anginosus* antigen that induces nitric oxide synthesis by murine peritoneal exudate cells, 952
SATO Y *see* YIMIN *et al.*, 688
SAXÉN H *see* JANTUNEN *et al.*, 650
SAYERS A R *see* RANDALL *et al.*, 919
SCHACKERT C *see* SCHALLER *et al.*, 743
SCHALLER M, JANUSCHKE E, SCHACKERT C, WOERLE B, KORTING H C. Different isoforms of secreted aspartyl proteinases (Sap) are expressed by *Candida albicans* during oral and cutaneous candidosis *in vivo*, 743
SCHEUTZ F *see* BANG *et al.*, 1087

SCHITO G C *see* MARCHISIO *et al.*, 1095
SCHLICHTING P *see* PETERSEN *et al.*, 96
SCHMIDT D *see* RATH AND SCHMIDT, 108
SCHNEIDER B S *see* ZEIDNER *et al.*, 1055
SCHØNHEYDER H C *see* NØRSKOV-LAURITSEN *et al.*, 636
SCHULTZ M J, RIJNEVELD A W, FLORQUIN S, SPEELMAN P, VAN DEVENTER S J H, VAN DER POLL T. Impairment of host defence by exotoxin A in *Pseudomonas aeruginosa* pneumonia in mice, 822
SHANG H, THONG J T W, GOPALAKRISHNAKONE P, LEE M A, YAP E P H, MOOCHHALA S, YAP E H. Production of oxalate in the culture supernate of *Burkholderia pseudomallei*, 655
SHARP R, FISHBAIN S, MACFARLANE G T. Effect of short-chain carbohydrates on human intestinal bifidobacteria and *Escherichia coli in vitro*, 152
SHEN Z *see* FOX *et al.*, 421
SHEPEL M, BOYD J, LUIDER J, GIBB A P. Interaction of *Yersinia enterocolitica* and *Y. pseudotuberculosis* with platelets, 1030
SHIMADA T *see* CHAKRABORTY *et al.*, 879
SHIMADA T *see* MITRA *et al.*, 268
SHINA A *see* WINSTANLEY *et al.*, 255
SIITONEN A *see* JANTUNEN *et al.*, 650
SILVA S H, VIEIRA E C, DIAS R S, NICOLI J R. Antagonism against *Vibrio cholerae* by diffusible substances produced by bacterial components of the human faecal microbiota, 161
SIMPSON A J H. Melioidosis: a clinical model for gram- negative sepsis, 657
SINGH H *see* KUMAR *et al.*, 489
SINGH R *see* AHLUWALIA *et al.*, 83
SIU L K *see* WANG *et al.*, 277
SKUSE A M *see* WALES *et al.*, 752
SMITH A *see* RIGGIO *et al.*, 249
SMITH A J, JACKSON M S, BAGG J. The ecology of *Staphylococcus* species in the oral cavity, 940
SMITH H R *see* WILLSHAW *et al.*, 135
SMITS H L *see* MARRODAN *et al.*, 663
SOBANSKI M A, STEPHENS J, BIAGINI G A, COAKLEY W T. Detection of adenovirus and rotavirus antigens by an immunogold lateral flow test and ultrasound-enhanced latex agglutination assay, 203
SOBREIRA M, LEAL N C, MAGALHÃES M, GUTH B E C, ALMEIDA A M P. Molecular analysis of clinical isolates of *Providencia alcalifaciens*, 29
SOJKA M *see* NAUGHTON *et al.*, 1049
SÓKI J, EDWARDS R, URBÁN E, FODOR E, NAGY E. A clinical isolate of *Bacteroides fragilis* from Hungary with high-level resistance to imipenem, 107
SÓKI J *see* URBÁN *et al.*, 1082
SONG K P *see* TAN *et al.*, 613
SPEELMAN P *see* SCHULTZ *et al.*, 822
SPEERT D P *see* CHIU *et al.*, 594
SPERLING-PETERSEN H U *see* NØRSKOV-LAURITSEN *et al.*, 636
SPIGAGLIA P, CARDINES R, ROSSI S, MENOZZI M G, MASTRANTONIO P. Molecular typing and long-term comparison of *Clostridium difficile* strains by pulsed- field gel electrophoresis and PCR-ribotyping, 407
SPIGELMAN M *see* DONOGHUE *et al.*, 177
SPRATT D A *see* DOWNES *et al.*, 947
SRIDHAR S *see* AHLUWALIA *et al.*, 83
STABEL J R *see* BANNANTINE AND STABEL, 795
STAEHELI P, LIEB K. Bornavirus and psychiatric disorders – fact or fiction?, 579
STAGG D A *see* DIBB-FULLER *et al.*, 759
STANLEY J *see* GRADY *et al.*, 588
STANLEY P J *see* PEDRAZA-DÍAZ S *et al.*, 293
STEPHENS J *see* SOBANSKI *et al.*, 203
STEVENS D A *see* AHLUWALIA *et al.*, 83
STOCK I, WIEDEMANN B. Natural antibiotic susceptibility of *Klebsiella pneumoniae*, *K. oxytoca*, *K. planticola*, *K. ornithinolytica* and *K. terrigena* strains, 396
STRLE F *see* RUZIC-SABLJIC *et al.*, 896
STURM A W *see* MAKAKOLE AND STURM, 449
SUKWATTANAPAN C *see* UBOL *et al.*, 238
SUMMERSGILL J T *see* SAHNEY *et al.*, 517
SUR S K *see* CHATTOPADHYAY *et al.*, 933
SUZUKI L A, ROCHA R J, ROSSI C L. Evaluation of serological markers for the immunodiagnosis of acute acquired toxoplasmosis, 62
SVENSSON L A *see* AHMED *et al.*, 860
SYMOENS F *see* CIMON *et al.*, 367
SYMOENS F *see* ZOUHAIR *et al.*, 925
SZEIMIES U *see* ZINK *et al.*, 355

TAJIKA S *see* SASAKI *et al.*, 952
TAKADA H *see* MONODANE *et al.*, 4
TAKADA H *see* SAKUTA *et al.*, 233
TAKAHASHI A, IIDA T, NAIM R, NAYKAYA Y, HONDA T. Chloride secretion induced by thermostable direct haemolysin of *Vibrio parahaemolyticus* depends on colonic cell maturation, 870
TAKAKUWA H *see* KATO *et al.*, 720
TAKEDA Y *see* CHAKRABORTY *et al.*, 879
TAKEDA Y *see* MITRA *et al.*, 268
TAN K S, WEE B Y, SONG K P. Evidence for holin function of *tcdE* gene in the pathogenicity of *Clostridium difficile*, 613
TANSEL O *see* VAHABOGLU *et al.*, 642
TARELLI E *see* ROBERTS *et al.*, 620
TARKKA E *see* DOWNES *et al.*, 947
TARRAND J *see* KONTOYIANNIS *et al.*, 78
TATEDA K *see* MIYAZAKI *et al.*, 695
TATEDA K *see* YOSHIDA *et al.*, 456, 959
TATMAN-OTKUN M *see* VAHABOGLU *et al.*, 642
TAYLOR A *see* OLD *et al.*, 415
TAYLOR-ROBINSON D, FURR P M. Failure of *Mycoplasma pneumoniae* infection to confer protection against *Mycoplasma genitalium*: observations from a mouse model, 383
TEIXEIRA L A *see* SANTOS SOARES *et al.*, 732
TENOVUO J *see* IHALIN *et al.*, 42
TERYOSHKINA N Y *see* FEODOROVA *et al.*, 499
THOMSON A P J *see* HACKETT *et al.*, 847
THONG J T W *see* SHANG *et al.*, 655
THORNS C J *see* NAUGHTON *et al.*, 1049
THUNGAPATHRA M *see* CHAKRABORTY *et al.*, 879
TOGNON M, MARTINI F, IACCHERI L, CULTRERA R, CONTINI C. Investigation of the simian polyomavirus SV40 as a potential causative agent of human neurological disorders in AIDS patients, 165
TORII M *see* SAKUTA *et al.*, 233
TOTET A *see* NEVEZ *et al.*, 198
TOWNER K J *see* GALLEGO AND TOWNER, 71
TRAN MANH SUNG R *see* HAFID *et al.*, 1100
TSAKRIS A *see* ARVANITIDOU *et al.*, 1001
TSAO N, HSU H P, WU C M, LIU C C, LEI H Y. Tumour necrosis factor-α causes an increase in blood-brain barrier permeability during sepsis, 812
TSAO S-M, YIN M-C. In-vitro antimicrobial activity of four diallyl sulphides occurring naturally in garlic and Chinese leek oils, 646
TSOI H-W *see* WOO *et al.*, 330
TSUJIMOTO S *see* YOSHIDA *et al.*, 456, 959
TULLIS E *see* SAJJAN *et al.*, 535
TURNER T *see* NYE *et al.*, 472, 659

UBOL S, SUKWATTANAPAN C, MANEERAT Y. Inducible nitric oxide synthase inhibition delays death of rabies virus-infected mice, 238
UCHIDA K *see* YOSHIDA *et al.*, 456, 959
UDO E E, JACOB L E, MATHEW B. Genetic analysis of methicillin-resistant *Staphylococcus aureus* expressing high- and low-level mupirocin resistance, 909
UDO E E *see* AL-HADDAD *et al.*, 558
ULDUM S A *see* HELBIG *et al.*, 509
ULLMANN U *see* PODSCHUN *et al.*, 208
ULRICH M *see* HEININGER *et al.*, 243
UNERTL K *see* HEININGER *et al.*, 243
UPADHYAY S N *see* AGARWAL *et al.*, 653
URBÁN E, BRAZIER J S, SÓKI J, NAGY E, DUERDEN B I. PCR ribotyping of clinically important *Clostridium difficile* strains from Hungary, 1082
URBÁN E *see* SÓKI *et al.*, 107
UTT M *see* FALLGREN *et al.*, 547

VADIVELU J *see* CHENTHAMARAKSHAN *et al.*, 55
VAHABOGLU H, COSKUNKAN F, TANSEL O, OZTURK R, SAHIN N, KOKSAL I, KOCAZEYBEK B, TATMAN-OTKUN M, LEBLEBICIOGLU H, OZINEL M A, AKALIN H, KOCAGOZ S, KORTEN V. Clinical importance of extended-

spectrum β-lactamase (PER-1- type)-producing *Acinetobacter* spp. and *Pseudomonas aeruginosa* strains, 642
VAHERI A *see* AALTONEN *et al.*, 468
VALASSINA M, MIGLIORINI L, SANSONI A, SANI G, CORSARO D, CUSI M G, VALENSIN P E, CELLESI C. Search for *Chlamydia pneumoniae* genes and their expression in atherosclerotic plaques of carotid arteries, 228
VALENSIN P E *see* VALASSINA *et al.*, 228
VAN ALPHEN L *see* RINGROSE *et al.*, 385
VAN DER POLL T *see* SCHULTZ *et al.*, 822
VAN DEVENTER S J H *see* SCHULTZ *et al.*, 822
VAN LOOVEREN M, CAUGANT D A, CHAPELLE S, CARION F, GOOSSENS H. Interpreting the rising incidence of meningococcal disease in Belgium: the contribution of molecular typing, 986
VAN SOOLINGEN D, ARBEIT R D. Dealing with variation in molecular typing of *Mycobacterium tuberculosis*: low-intensity bands and other challenges, 749
VARGAS M *see* VILA *et al.*, 996
VIEIRA E C *see* SILVA *et al.*, 161
VILA J, VARGAS M, RUIZ J, ESPASA M, PUJOL M, CORACHÁN M, JIMÉNEZ DE ANTA M T, GASCÓN J. Susceptibility patterns of enteroaggregative *Escherichia coli* associated with traveller's diarrhoea: emergence of quinolone resistance, 996
VISVESVARA G S *see* MARTÍNEZ AND VISVESVARA, 205

WADE W G *see* DOWNES *et al.*, 947
WADSTRÖM T *see* ANNUK *et al.*, 1069
WADSTRÖM T *see* RUIZ-BUSTOS *et al.*, 215
WADSTRÖM T *see* WANG *et al.*, 430
WALES A D, PEARSON G R, SKUSE A M, ROE J M, HAYES C M, COOKSON A L, WOODWARD M J. Attaching and effacing lesions caused by *Escherichia coli* O157:H7 in experimentally inoculated neonatal lambs, 752
WANG C-C, SIU L K, CHEN M-K, YU Y-L, LIN F M, HO M, CHU M- L. Use of automated riboprinter and pulsed-field gel electrophoresis for epidemiological studies of invasive *Haemophilus influenzae* in Taiwan, 277
WANG W-B *see* LIAW *et al.*, 1039
WANG X, HIRMO S, WILLÉN R, WADSTRÖM T. Inhibition of *Helicobacter pylori* infection by bovine milk glycoconjugates in a BALB/cA mouse model, 430
WARREN R E *see* NYE *et al.*, 472, 659
WEE B Y *see* TAN *et al.*, 613
WENDT M *see* KRZYMINSKA *et al.*, 303
WHEELER P R. Understanding the physiology of difficult, pathogenic bacteria from analysis of their genome sequences, 843
WHITTAKER S *see* ZADIK *et al.*, 476
WIEDEMANN B *see* STOCK AND WIEDEMANN, 396
WIEDMANN-AL-AHMAD M *see* FREIDANK *et al.*, 223
WILBY R *see* MARSHALL *et al.*, 143
WILLÉN R *see* WANG *et al.*, 430
WILLIAMS P H *see* KUMAR *et al.*, 602
WILLSHAW G A, CHEASTY T, SMITH H R, O'BRIEN S J, ADAK G K. Verocytotoxin-producing *Escherichia coli* (VTEC) O157 and other VTEC from human infections in England and Wales: 1995–1998, 135
WINSTANLEY C, HART C A. Type III secretion systems and pathogenicity islands, 116
WINSTANLEY C, DETSIKA M G, GLENDINNING K J, PARSONS Y N, HART C A. Flagellin gene PCR-RFLP analysis of a panel of strains from the *Burkholderia cepacia* complex, 728
WINSTANLEY C, SHINA A, DAWSON S, GASKELL R M, HART C A. Variation in *Bordetella bronchiseptica flaA* does not correlate with typing by macro-restriction analysis by pulsed-field gel electrophoresis, 255
WINSTANLEY C *see* DEMIRKAN *et al.*, 1061
WIRSING VON KÖNIG C H *see* KÖSTERS *et al.*, 436
WLODARCZAK K *see* KRZYMINSKA *et al.*, 303
WOERLE B *see* SCHALLER *et al.*, 743
WOODFORD N *see* DEMERTZI *et al.*, 682
WOODSIDE M *see* DEMIRKAN *et al.*, 1061
WOODWARD M J *see* DIBB-FULLER *et al.*, 759
WOODWARD M J *see* NAUGHTON *et al.*, 191
WOODWARD M J *see* RANDALL AND WOODWARD, 770
WOODWARD M J *see* RANDALL *et al.*, 919
WOODWARD M J *see* WALES *et al.*, 752
WOO P C-Y, LEUNG P K-L, TSOI H-W, YUEN K-Y. Cloning and characterisation of *malE* in *Burkholderia pseudomallei*, 330
WOO W H *see* JUNG *et al.*, 35
WRIGHT P J *see* MARSHALL *et al.*, 143
WU C *see* MAGNARELLI *et al.*, 889
WU C M *see* TSAO *et al.*, 812

XU S *see* FOX *et al.*, 421

YAMAGISHI T *see* KATO *et al.*, 720
YAMAGUCHI K *see* MIYAZAKI *et al.*, 695
YAMAGUCHI K *see* YOSHIDA *et al.*, 456, 959
YAMAGUCHI N *see* SAKUTA *et al.*, 233
YAMASAKI S *see* CHAKRABORTY *et al.*, 879
YAMASAKI S *see* MITRA *et al.*, 268
YAMAURA C *see* SASAKI *et al.*, 952
YANAGISAWA N, LI D-Q, LJUNGH A. The N-terminal of thrombospondin-1 is essential for coagulase-negative staphylococcal binding, 712
YANG S *see* MONODANE *et al.*, 4
YAP E H *see* SHANG *et al.*, 655
YAP E P H *see* SHANG *et al.*, 655
YARD B A *see* RINGROSE *et al.*, 385
YIMIN, KOHANAWA M, SATO Y, MINAGAWA T. Role of T cells in granuloma formation induced by *Rhodococcus aurantiacus* is independent of their interferon-gamma production, 688
YIN M-C *see* TSAO AND YIN, 646
YOSHIDA K, MATSUMOTO T, TATEDA K, UCHIDA K, TSUJIMOTO S, IWAKURA Y, YAMAGUCHI K. Protection against pulmonary infection with *Klebsiella pneumoniae* in mice by interferon-γ through activation of phagocytic cells and stimulation of production of other cytokines, 959
YOSHIDA K, MATSUMOTO T, TATEDA K, UCHIDA K, TSUJIMOTO S, YAMAGUCHI K. Induction of interleukin-10 and down- regulation of cytokine production by *Klebsiella pneumoniae* capsule in mice with pulmonary infection, 456
YOU J-C *see* KANG *et al.*, 675
YUEN K-Y *see* WOO *et al.*, 330
YU Y-L *see* WANG *et al.*, 277
YUEN L K W *see* MARSHALL *et al.*, 143
YADAV R P *see* AGARWAL *et al.* 653

ZADIK P M, DAVIES S, WHITTAKER S, MASON C. Evaluation of a new selective medium for methicillin-resistant *Staphylococcus aureus*, 476
ZEIDNER N S, NúNCIO M S, SCHNEIDER B S, GERN L, PIESMAN J, BRANDÃO O, FILIPE A R. A Portuguese isolate of *Borrelia lusitaniae* induces disease in C3H/HeN mice, 1055
ZINK A, HAAS C J, REISCHL U, SZEIMIES U, NERLICH A G. Molecular analysis of skeletal tuberculosis in an ancient Egyptian population, 355
ZOUHAIR R, DEFONTAINE A, OLLIVIER C, CIMON B, SYMOENS F, HALLET J-N, DEUNFF J, BOUCHARA J-P. Typing of *Scedosporium apiospermum* by multilocus enzyme electrophoresis and random amplification of polymorphic DNA, 925
ZOUHAIR R *see* CIMON *et al.*, 367